Localized Tolerance and Development of an Alternative Transplant Site to Treat Type 1 Diabetes by Skoumal, Michael













A dissertation submitted in partial fulfillment 
of the requirement for the degree of  
Doctor of Philosophy  
(Chemical Engineering) 















Professor Lonnie D. Shea, Chair 
Assistant Professor Timothy Scott 
Professor Jan P. Stegemann 
















































 Thank you everybody who has supported me on this journey. And not just the PhD 
journey, but all the steps that led me here. It is certain that without your support, I would never 
have been able to have the opportunity to get where I am. Thank you, Lonnie, for your 
guidance, insight, and dedication. Thank you Professors Scott, Stegemann, and Thurber for your 
time and excellent input. And thank you, Pat, for your wizardry.  
 Thank you to Stephanie and Ryan (Pearson) for enduring my constant questions about 
biochemistry. I feel like most of the conversations usually ended with, “It’s thermodynamics, 
that’s just how it is,” but I appreciated that you humored me and my long chain of questions. 
Hannah, Ryan (Boehler), and Jackie – thank you for getting me acquainted with the lab and 
setting the culture in our awesome L.A.B. I’m sure you’d be surprised how much the lab has 
changed since you graduated, and you might be not be surprised how much certain aspects 
have stayed the same. At least we have larger lab coats now. Thank you to Daniel and Jeff for 
meaningful collaborations. And thank you to Richard, who has the task of continuing this work. 
 Thank you to my friends outside the lab, particularly my roommates Emily, Yamil, 
Teresa, and Erik. Without your support, I would have surely lost my mind. Thank you to my 
friends back in Iowa, particularly Ravi and Eric, who always set an example in excellence that I 
hope to follow. Finally, I would like to thank my family, particularly my parents. I know you 
would have liked me to be a real doctor, but Mike Rea was too persuasive. Engineering really is 




TABLE OF CONTENTS 
DEDICATION ii 
ACKNOWLEDGMENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES viii 
ABSTRACT xiv 
CHAPTER 1. Introduction 1 
1.1 Motivation and objective 1 
1.2 Overview of this dissertation 2 
CHAPTER 2. Background 4 
2.1 Introduction 4 
2.2 Alternative transplant sites 6 
2.3 Biomaterial scaffolds 10 
2.4 Viral delivery of soluble factors 12 
2.5 Immunoregulation 14 
CHAPTER 3. Evaluation of Encapsulating and Microporous Hydrogel Scaffold Designs on Islet 
Engraftment in Rodent Models of Diabetes 17 
3.1 Introduction 17 
3.2 Materials and methods 19 
3.2.1 Encapsulated and microporous hydrogel fabrication 19 
3.2.2 Islet isolation and transplantation 21 
3.2.3 Intraperitoneal glucose tolerance test 22 
3.2.4 Immunohistochemistry 22 
3.3 Results 23 
3.3.1 Encapsulating and Microporous Hydrogel Fabrication 23 
3.3.2 Syngeneic islet transplants in encapsulating and microporous hydrogels 26 
3.3.3 Histological Analysis of Hydrogel Explants from Syngeneic Transplants 29 
3.3.4 Allogeneic Islet Transplants in Encapsulating and Microporous Hydrogels 31 
3.3.5 PEG hydrogels create a microenvironment conducive to islet survival 34 
v 
 
3.4 Discussion 36 
CHAPTER 4. Localized Lentivirus Delivery via Affinity Peptides 41 
4.1 Introduction 41 
4.2 Materials and methods 42 
4.2.1 Virus production 42 
4.2.2 PLL functionalization with cysteine 43 
4.2.3 Macrophage differentiation 44 
4.2.4 Peptide synthesis 44 
4.2.5 Biotinylated VSV-G 44 
4.2.6 Solution phase phage display 45 
4.2.7 ELISA 46 
4.2.8 Hydrogel preparation 46 
4.2.9 Transgene expression 47 
4.2.10 Statistics 47 
4.3. Results 48 
4.3.1 PLL length 48 
4.3.2 Binding dynamics, release, and stability 50 
4.3.3 VSV-G protein solution-phase panning 52 
4.4 Discussion 59 
CHAPTER 5. Localized Immune Tolerance from FasL-Functionalized PLGA Scaffolds 64 
5.1 Introduction 64 
5.2 Materials and methods 66 
5.2.1 Biotinylation of PLGA and characterization 67 
5.2.2 Particle and scaffold fabrication 67 
5.2.3 Particle characterization 68 
5.2.4 Scanning electron microscopy 68 
5.2.5 Protein loading and quantification 68 
5.2.6 Apoptosis assay 69 
5.2.7 Mice and recombinant proteins 69 
5.2.8 Islet isolation and engineering with SA-FasL protein 70 
5.2.9 Islet transplantation 70 
vi 
 
5.2.10 Intraperitoneal Glucose Tolerance Test 71 
5.2.11 Immune monitoring 71 
5.2.12 Statistical analysis 72 
5.3 Results 72 
5.3.1 Transplantation of SA-FasL modified islets onto microporous scaffolds 72 
5.3.2 Synthesis and characterization of biotin-poly(lactide-co-glycolide) conjugates and 
particle formation 74 
5.3.3 FasL loading on biotin-PLGA scaffolds 79 
5.3.4 FasL scaffolds support allogeneic graft function without sustained 
immunosuppression 81 
5.4 Discussion 84 
CHAPTER 6. Conclusions and Future Directions 89 
6.1 Conclusions 89 
6.2 Future directions 91 
6.2.1 Scaffold improvement 91 










LIST OF TABLES 
Table 3-1. Particle size of gelatin and salt particles used as a porogen for microporous 
hydrogels. Mean is reported with standard error mean. Gelatin (n = 52), salt (n=41). 25 
Table 4-1. Equal masses of the different poly-L-lysines were added to provide an identical net 
charge for each condition. 49 
















LIST OF FIGURES 
 
Figure 3-1. Fabrication of PEG-maleimide hydrogels. (A) Encapsulated hydrogels are formed by 
mixing the peptide cross linker GCYKNRGCYKNRCG with a PEG/islet solution in a PDMS mold. 
Cross linking is induced via Michael-type reaction between the thiols in the peptide and the 
maleimide groups on the PEG. (B) Microporous hydrogels are formed by packing gelatin 
particles into a PDMS mold and adding PEG. After initiating free-radical polymerization via UV 
light and the photoinitiator I-2959, the gelatin particles are leached out at 37 oC, leaving a 
porous hydrogel that can be seeded with islets. (C) Microporous hydrogels with salt pores are 
formed in a manner similar to the gelatin microspheres, but require the PEG precursor solution 
to be saturated with salt prior to being added to the salt-packed PDMS mold. After 
polymerization, the salt is quickly leached out and the scaffold can be seeded with islets. 24 
Figure 3-2. Encapsulating and microporous hydrogels for islet transplantation. (A) 10% (wt/vol) 
bulk PEG hydrogels were fabricated to encapsulate islets. (B) Gelatin particles (size = 107± 4 
μm, n =41) were fabricated, incorporated into 20% PEG (wt/vol), and subsequently leached to 
form a (C-D) resultant hydrogel with a microporous architecture for islet seeding. Similarly, (E) 
salt particles (size = 274 ±12 μm, n = 41) were incorporated into 20% PEG (wt/vol) to form a (F-
G) microporous gel for islet seeding. Scale bar:  1 mm (A, C, F), 100 μm (B), 200μm (D,E,G). Gels 
were stained with sirius red for visualization. 25 
Figure 3-3. Blood glucose monitoring post-transplant with hydrogel materials in fat pad 
transplantation site of diabetic mice. (A) Bulk, non-degradable encapsulating hydrogels with 
700 IEQ reversed diabetes in recipient mice, and approached normoglycemic levels by Day 12 
(<200 mg/dL), with consistent normoglycemia achieved after Day 17 (n=3, ± SEM).  (B) A 
gelatin-leached, microporous hydrogel seeded with 700 IEQ (400 islets) reversed diabetes in a 
recipient mouse by Day 10 and displayed long-term function until graft removal at Day 106 
(n=1, ± SEM). (C) Gelatin-leached, microporous hydrogels seeded with 200 islets reversed 
diabetes in recipient mice by Day 9 (n=4, ± SEM). Mice receiving a PLGA scaffold, used an 
internal control due to success in previous studies, reversed a few days earlier, by Day 7 (n=1). 
(D) Salt-leached, microporous hydrogels seeded with 700 IEQ displayed normoglycemic levels 
as early as Day 1 post-transplant, and consistently maintained normoglycemia after Day 15 (n=5 
pre-graft removal, n=4 post-graft removal, ± SEM). Recipient mice in all groups reverted to a 
diabetic state within 2-4 days following hydrogel removal (indicated with a black arrow). 28 
Figure 3-4. Glucose responsiveness of microporous hydrogels. (A) Encapsulated hydrogels with 
700 IEQ (n=5, ± SEM) achieved normoglycemia (<200 mg/dL) 120 minutes post-glucose 
injection. In contrast, (B) mice receiving gelatin-leached, microporous hydrogels with 200 islets 
(n=4, ± SEM), a PLGA scaffold with 200 islets (n=1), or (C) salt-leached, microporous scaffolds 
ix 
 
with 700 IEQ (n=5, ± SEM) achieved normoglycemia 60 minutes post-glucose injection, similarly 
to control mice with native pancreata. IPGTT performed at Day 32 (A), and Day 30 (B) post-
transplant. 30 
Figure 3-5. Insulin-positive islets confirmed in microporous hydrogels (A-B) Insulin-positive 
islets were identified in gelatin-leached, microporous scaffolds removed at Day 32 and (C) salt-
leached, microporous scaffolds removed at Day 30 (Scale bar: 100 μm). (D) Explanted salt-
leached microporous hydrogel 1 month post-transplant. Histology for encapsulated hydrogels 
will be completed in the near-future. 32 
Figure 3-6. Allogeneic transplants failed to engraft before rejection. (A) Encapsulating hydrogels 
with 500 (n=4,± SEM) or 1,000 islets (n = 2, ± SEM) are unable to maintain normal blood glucose 
levels more than 2 weeks post-transplant, indicating encapsulation alone is not sufficient to 
prevent graft rejection. (B) With the exception of one mouse (blue line), salt-leached 
microporous hydrogels with an IEQ of 1300 failed to achieve normoglycemia. 33 
Figure 3-7. Transforming growth factor-β1 (TGF-β1) in vitro release from PLGA scaffolds and 
incorporation into hydrogel materials. (A) A cumulative release of 0.66 µg was determined from 
PLGA disc loaded with 2 µg of TGF-β1.  (B) More than 80 % of total protein was released by Day 
3 (n = 5, ± SEM). (C) For encapsulating hydrogel transplants, a PLGA disc containing 2 µg of was 
placed on top of the hydrogel and wrapped in the fat pad. (D) For microporous hydrogels, the 
PLGA disc containing 2 µg was incorporated into the middle of the hydrogel. (E) Cross-section 
view of PLGA scaffold in microporous hydrogel. (F) Islets seeded on a microporous scaffold. A 
representative islet is indicated with a white arrow. 35 
Figure 3-8. Allogeneic graft function of scaffolds with TGF-β1 (A) Encapsulating hydrogels 
combined with TGF-β1 delivery delays rejection until Day 24 compared to rejection at Day 12 
without TGF-β1 (n = 2 per group, ± SEM). Rejection is denoted as two consecutive days of blood 
glucose >250 mg/dL. (B) Graft Function 7-days post-transplant in salt-leached microporous 
hydrogels. - TGF-β1 condition (n=2, ± SEM), + TGF-β1 condition (n=4, ± SEM). At day 7, the 
microporous hydrogels were removed for flow cytometry. 37 
Figure 4-1. Influence of PLL molecular weight on virus localization. PEG hydrogels containing 2.5 
mM RGD were functionalized with 0.45 mg/mL of 1 kDa (n=3) (A), 10 kDa (n=3) (B), and 30-70 
kDa (n=5). (C) PLL and incubated with GFP-encoding lentivirus. Hydrogels were washed to 
remove non-binding virus then seeded with HT1080 cells for 72 hours. (D) Significantly more 
cells were transduced with 30-70 kDa PLL than the shorter PLL’s. (*p≤0.05; ***p≤0.001) 49 
Figure 4-2. PLL functionalized hydrogels promote transduction of macrophages. PEG hydrogels 
were functionalized with 2.5 mM RGD (A) and 2.5 mM RGD + 1.35 mg/mL of 30-70 kDa PLL (B). 
Conditions without PLL (A) had no GFP expression while PLL functionalized hydrogels 
demonstrated significant GFP expression (B). 49 
Figure 4-3. PLL enhances virus localization on PEG hydrogels. PEG hydrogels containing 2.5 mM 
RGD were functionalized with either 30-70 kDa PLL (0.45 mg/mL) or additional RGD (2.5 mM) 
x 
 
(n=3). Designated wells were blocked with BSA (5 mg/mL) prior to forming the hydrogels. The 
“No virus” condition contains PLL but was incubated with PBS instead of lentivirus. Lentivirus 
encoding for GLuc was incubated with the hydrogels then washed with PBS to remove non-
binding virus. HT1080 cells were incubated with the hydrogels for three days and then 
luciferase activity was assayed. Significant difference compared to No virus and RGD 
(****p≤0.0001). 51 
Figure 4-4. Transgene expression can be modulated via virus-hydrogel incubation time and PLL 
concentration. (A) PEG hydrogels functionalized with 2.5 mM RGD and 0.45 mg/mL of PLL were 
incubated with virus for varying times (n=3). Fold increase in GLuc expression relative to RGD 
control. Significant difference compared to RGD control (**p≤0.01; ***p ≤0.001). (B) Hydrogels 
were functionalized with varied concentrations of PLL and incubated with virus for 3 hours 
(n=3). Significant difference compared to RGD control (****p≤0.0001). 51 
Figure 4-5. Retention of lentivirus on PLL-functionalized PEG hydrogels. (A) PEG hydrogels 
containing 2.5 mM RGD were functionalized with either 30-70 kDa PLL or additional RGD (0.45 
mg/mL) (n=4). Virus was incubated with the hydrogels for three hours at 37 oC then washed 
with PBS to remove non-binding virus. Unbound virus in the supernatant was collected and 
assayed via qPCR at different time points. Following the two washes, no detectable level of 
virus was found in the PLL-functionalized hydrogels. (B) The fraction of lentivirus released from 
the hydrogel was calculated by dividing the eluted virus particles by the initial virus loading. 
Significant differences between corresponding RGD and PLL conditions are denoted by an 
asterisk (**p≤0.01; ****p≤0.0001). 53 
Figure 4-6. Increased viral stability in PLL-functionalized hydrogels at 37oC. PEG hydrogels with 
2.5 mM RGD and either 30-70 kDa PLL or additional RGD (0.45 mg/mL) were incubated with 
virus at 37 oC for three hours (n=3). All hydrogels were washed and incubated with PBS. At each 
time point, the PBS was replaced with HT1080 cells and subsequent luciferase expression was 
assayed 72 hours later. (**p≤0.01; ***p≤0.001) 54 
Figure 4-7. Analysis of lentivirus purification methods using SDS-PAGE protein gel. (Lane 1, 3 = 
VSV-G, 0.5 µg; lane 4, 5 = VSV-G, 2.0 µg; lane 6, 7 = Lentivirus, Lenti-X purification; lane 8, 9 = 
Lentivirus, PEG-it purification; lane 10 = ladder; Lane 2 intentionally left blank). The Lenti-X 
affinity column removed almost all detectable amounts of contaminating protein, except for a 
faintly detectable band at approximated 65 kDa whereas the PEG-it precipitation failed to 
remove significant amounts of undesired protein. 54 
Figure 4-8. Solution phase phage display. Biotinylated VSV-G and the phage library are mixed 
(1) and allowed to incubate (2). (3) Phage/VSV-G complexes are captured on a streptavidin-
coated plate and non-binding phages are washed away (4). VSV-G bound phages are eluted 
from the plate using a low pH buffer (5) and the phages are collected for additional rounds of 
panning. 56 
Figure 4-9. After three rounds of panning, phages demonstrate binding affinity to VSV-G. A 
fourth round of panning was completed with (+) and without (-) VSV-G immobilized on the 
xi 
 
plate surface. After washing to remove non-binding phages, 105 PFU/µL were eluted from the 
plate surface coated with VSV-G whereas only 10 PFU/µL. 56 
Figure 4-10. Relative variability analysis of the sequences derived from phage display shows a 
decreased variability at position 1 and 4-7. Position 12 is closest to the phage body and position 
1 has the most freedom of movement. This analysis removed any repeat sequences. 58 
Figure 4-11. ELISA results of the STQ phage shows increased binding compared to the naïve 
phage library. As the titer of phages added to VSV-G coated plates was increased, phages 
displaying the STQ sequence demonstrated increased binding whereas the non-specific naïve 
library did not demonstrate a noticeable change in binding. 58 
Figure 4-12. Phage display identified peptides specific to the VSV-G protein on the lentivirus. 
Specific binding of lentivirus to phage display peptides. PEG hydrogels were functionalized with 
2.5 mM RGD and 2.5 mM of the synthesized phage display peptides conjugated with a 5 kDa 
PEG linker (n=4). HLKHTHNTHYKTCG (“HLK”), HWKPHSNLHLSRCG (“HWK”), STQHHHHSKQSRCG 
(“STQ”), and WPGHHNHSMKHKCG (“WPG”). RGD and 30-70 kDa PLL (0.45 mg/mL) were also 
functionalized to the PEG linker to serve as negative and positive controls, respectively. 
Lentivirus was incubated with the hydrogels for 3 hours followed by washing to remove non-
binding virus. HT1080 cells were seeded on the hydrogels and luciferase activity was assayed 72 
hours later. Fold increase in GLuc expression relative to RGD control. Significant differences 
between RGD and PLL are denoted by an asterisk (p<0.05). 60 
Figure 5-1. SA-FasL engineered islets establish allogeneic tolerance when transplanted on PLGA 
scaffolds. (A) Schematic showing biotinylated allogeneic islets functionalized with SA-FasL are 
loaded on microporous PLGA scaffolds and planted in the epididymal fat pad of mice. (B) Kaplan 
Meier analysis of allogeneic BALB/c islets transplanted under the short cover of rapamycin on 
unmodified PLGA scaffolds in C57BL/6 recipients. Conditions include SA-FasL-engineered islets 
(n = 5, MST >200 days, P=0.0018 vs. rapamycin alone, P=0.0308), naïve islets (n = 5, MST = 23 
±2.19 days), and unmodified syngeneic islets (n = 3, MST > 100 days). (C) Intraperitoneal 
glucose tolerance test of long-term islet grafts compared to naïve C57BL/6 mice after fasting for 
6 hours, followed by i.p. glucose injection. Blood glucose of mice was taken starting just before 
injection and at the indicated time points. (D) T cell proliferative response from recipients of 
long-term (> 200 days) BALB/c SA-FasL-engineered islets mounted on unmodified PLGA 
scaffolds plus rapamycin (n = 3) and naïve C57BL/6 as controls (n = 3). Responders were labeled 
with CFSE and used against BALB/c donor and third party C3H stimulators in a standard ex vivo 
mixed lymphocyte reaction. After 4 days of culture, cells were stained with antibodies against 
CD4 and CD8 molecules and incubated with 7AAD to gate out dead cells before flow cytometry 
analysis. Bars represent mean and SEM. Asterisks represent level of significance (*p<0.05, 
**p<0.01) found by using a two-tailed Welch’s t-test. 74 
Figure 5-2. Characterization of biotin-PLGA microparticles. (A) Conjugation of NH2-PEG2-biotin 
to PLGA resulting in biotin-PLGA. (B) 1H-NMR of PLGA (top), biotin linker (middle), and biotin-
PLGA (bottom). (C) Size (860 ± 40 nm) and charge (-15.8 ± 4.98 eV) of biotin-PLGA particles was 
xii 
 
measured using dynamic light scattering (DLS). (D) Scanning electron microscope (SEM) image 
of biotin-PLGA particles. 77 
Figure 5-3. Blending unmodified PLGA with biotin-PLGA is necessary to consistently form 
spherical particles. (A) SEM image of particles formed only with biotin-PLGA formed unstable 
particles. (B) Two ratios of biotin-PLGA : PLGA (50:50 and 75:25) were analyzed. There was no 
significant difference in SA binding between the two blends. 78 
Figure 5-4. Biotin-PLGA particles can be efficiently conjugated with SA-FasL and induce 
apoptosis in mouse B lymphoma cell line. (A) Schematic of biotin-PLGA particles being 
functionalized with SA-FasL. (B) The amount of fluorescently tagged SA bound to the particles 
was investigated by varying the protein concentration (0, 100, 200, 400, 800, and 40,000 ng 
SA/mL in 1 mL) incubated with 1 mg of biotin-PLGA particles (“biotin particles”). As a control, 1 
mg of unmodified PLGA particles was incubated with the same SA concentrations (“blank 
particles”). After two spins and washes, particles were dissolved in DMSO and fluorescence was 
measured, n=3. (C) The loading efficiency was calculated by dividing the bound SA by the 
incubated SA, n=3. (D) Biotin-PLGA particles functionalized with SA-FasL induce cell death in 
A20 cells. Particles were incubated with 400 ng / mL of SA-FasL in 1 mL with 1 mg of particles. 
After washing to remove unbound SA-FasL, particles were incubated with 1.5 x 105 A20 cells for 
18 hours and cell death was analyzed via propidium iodide stain and flow cytometry (n=3). For 
comparison, soluble FasL was added to cells (0 and 10 ng) and demonstrated the ability to 
induce cell death at low concentrations (n=3). 80 
Figure 5-5. Biotin-PLGA scaffolds can be efficiently conjugated with SA-FasL. (A) Schematic of 
biotin-PLGA particles functionalization with SA-FasL. (B) The amount of fluorescently tagged SA 
bound to scaffolds was investigated by varying the protein concentration (0, 100, 200, 400, and 
800 ng SA/20µL) incubated with 2.5 mg biotin-PLGA scaffolds (“biotin”). As a control, 
unmodified PLGA scaffolds were incubated with the same SA concentrations (“blank”). After 
two washes, scaffolds were dissolved in DMSO and fluorescence was measured, n=3. (C) The 
loading efficiency was calculated by dividing the bound SA by the incubated SA, n=3. 82 
Figure 5-6. FasL-decorated scaffolds induce apoptosis in mouse lymphoma cell line. (A) 
Scaffolds were incubated with SA-FasL (0, 40, 200, and 400 ng / 20 µL). After washing to remove 
unbound SA-FasL, scaffolds were incubated with 1.5 x 105 A20 cells for 18 hours. Apoptotic and 
dead cells were analyzed via propidium iodide and annexin V staining and flow cytometry (n=3). 
(B) Scaffolds required a minimum loading of 200 ng FasL / mg scaffold to induce apoptosis in 
the majority of A20 cells. 83 
Figure 5-7: Islets on scaffolds conjugated with SA-FasL demonstrate robust long-term tolerance. 
(A) Survival of allogeneic BALB/c islets mounted on PLGA scaffolds and transplanted in the 
epididymal fat pad of chemically diabetic C57BL/6 recipients. Groups included naïve islets 
mounted on SA-FasL-engineered PLGA scaffolds plus rapamycin (n = 6, MST > 200 days, 
P=0.0007 vs rapamycin alone), SA-FasL-engineered islets mounted on SA-FasL-engineered PLGA 
scaffolds (n = 6, MST = 46 days, P = 0.0007 vs rapamycin alone), and naïve islets transplanted 
xiii 
 
under a short cover of rapamycin (n = 5, MST = 23 ±2.19 days). All mice received islets loaded 
on 2 PLGA scaffolds. PLGA scaffolds were engineered with 2.5 μg/scaffold, except 3 mice in the 
islet-FasL+PLGA-SA-FasLthat were transplanted with PLGA scaffolds engineered with 
0.5μg/scaffold and all 3 animals rejected their grafts. Rapamycin was given to the indicated 
groups through i.p. injection at 0.2 mg/kg daily for 15 days starting on the day of 
transplantation. Mice were monitored twice weekly for blood glucose levels. Those with > 250 
mg/dL for two consecutive readings 24 hours apart were considered diabetic and rejecting the 
graft. Analysis done using log-rank test, **P<0.01, ***P<0.001. (B) Blood glucose readings of 
two groups of mice from (A). (C) Intraperitoneal glucose tolerance test (IPGTT) of long-term 
islet grafts compared to naïve C57BL/6 mice after fasting for 6 hours, followed by i.p. glucose 
injection. Blood glucose of mice was taken starting just before injection and at the indicated 







Islet transplantation is an attractive treatment for type 1 diabetes (T1D) to restore the 
body’s ability to endogenously produce insulin and rapidly respond to changes in blood glucose 
levels. Current clinical strategies where donor islets were intrahepatically transplanted have 
demonstrated success in a small number of patients. However, the widespread use of this 
approach is limited due the generation of allo- and autoimmune responses, which contributes to 
significant islet loss and eventual graft failure. This dissertation presents the development of an 
extrahepatic biomaterial scaffold that creates an alternative transplant site for the localized 
delivery of soluble factors and immunoregulatory proteins to enhance long-term transplant 
function. Two scaffold designs were employed to improve islet cell transplantation and explore 
the effects of different scaffold architectures on islet engraftment in the form of encapsulating 
and microporous polyethylene glycol (PEG)-based hydrogels to support islet function in the fat 
pad transplantation site of mice using syngeneic and allogeneic models. This allowed for the 
unique comparison of encapsulation and microporous techniques with the same material. 
Microporous hydrogels demonstrated rapid response to glucose challenge and were quickly 
infiltrated by host tissue. In contrast, islet-encapsulating PEG hydrogels both engraft and respond 
to fluctuations in blood glucose slower than microporous scaffolds. To modulate the local 
inflammatory environment, transforming growth factor β 1 (TGF-β1) was delivered from the PEG 
hydrogels and delayed rejection of allogeneic islets. Methods for sustained delivery of soluble 
factors were further explored by utilizing affinity peptides to localize lentiviral vectors for viral 
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gene delivery. Poly-L-lysine (PLL), a cationic polypeptide, was covalently attached to PEG 
hydrogels and demonstrated the ability to modulate the extent of virus adsorption and increase 
the half-life of the adsorbed virus by 20%. An alternative to PLL was discovered through phage 
display technology, with peptide sequences specific for the glycoprotein of the vesicular 
stomatitis virus (VSV-G) ectodomain, an envelope protein pseudotyped on the virus. These short, 
12 amino acid affinity peptides were easily incorporated into the hydrogel, and reporter protein 
expression was increased 20-fold relative to control peptide, comparable to levels observed with 
the high molecular weight PLL. Finally, the modification of biomaterials scaffolds with Fas ligand 
(FasL) was explored to create an immunoprivileged microenvironment that is translatable to the 
clinic. Poly(lactide-co-glycolide) (PLGA) was conjugated with biotin and fabricated into particles 
and microporous scaffolds to allow for rapid and efficient conjugation with the chimera protein 
streptavidin-FasL (SA-FasL). PLGA particles and microporous scaffolds coated with FasL 
demonstrated the ability to induce apoptosis in a mouse B lymphoma cell line. Scaffolds were 
functionalized with FasL, seeded with islets from BALB/c donors, and implanted in epididymal fat 
pad C57BL/6 recipients. Scaffolds with FasL and a short course treatment of rapamycin restored 
euglycemia and showed robust tolerance indefinitely without the sustained use of 
immunosuppressive drugs. Together, this dissertation presents work that will further our 






CHAPTER 1. Introduction 
 
1.1 Motivation and objective  
Type 1 diabetes (T1D) is a disorder that affects up to 3 million people in the United States 
and results from destruction of ß-cells in the pancreas by autoreactive immune cells [1]. The 
disease requires constant management of the patient’s diet and activity in addition to frequent 
monitoring of the blood glucose level. Although insulin can be produced through exogenous 
sources and administered via intramuscular injections or subdermal pumps, these treatments do 
not entirely prevent serious symptoms such as kidney failure, blindness, and tissue necrosis [2-
5]. The highly dynamic nature of blood glucose levels makes regulating it with injections 
challenging and still leaves patients prone to complications [6]. 
An attractive alternative to insulin therapy is cell replacement therapy due to its ability to 
endogenously produce insulin and rapidly respond to changes in blood glucose levels. Due to 
these properties, islet transplants have been associated with reducing progression of diabetic 
microvascular diseases [7]. In order to provide long-term function, therapies must be developed 
that address immune system challenges and improve transplantation efficiency. The goal of this 
dissertation is to develop novel tools that modify the microenvironment and provide signals to 
resident cells that encourage tissue regeneration. By developing hydrogel scaffolds, which 
control cell-material interactions, an improved and translatable microenvironment was created 
that serves as a platform for future studies. These scaffolds were modified to locally deliver viral 
vectors which serve as a method to induce expression of therapeutically relevant proteins. 
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Additionally, scaffolds were modified with immunoregulatory proteins that locally modulate the 
immune system in order to prolong survival of transplanted cells. 
1.2 Overview of this dissertation  
 Following the introductory chapter, Chapter 2 provides background information for topics 
relevant to the experimental work. After Chapter 2.1 provides an overview on current clinical 
treatments for T1D, Chapter 2.2 describes alternatives to portal vein transplantation. Chapter 2.3 
covers biomaterials and their relation to treating T1D. Chapter 2.4 considers gene delivery and 
their importance in delivering soluble factors. Chapter 2.5 reviews techniques utilized to regulate 
the immune system in allogeneic transplants.  
The experimental work in this dissertation was focused on modulating the islet 
microenvironment to promote transplantation survival. Chapter 3 developed PEG hydrogel 
scaffolds as alternative transplant site and explored how hydrogel architecture affects islet 
engraftment and survival. In addition to encapsulating and microporous designs, short-term 
localized protein delivery was demonstrated.  
Chapter 4 discovered affinity peptides that bind lentivirus to enhance gene delivery from 
hydrogels. Although viral gene delivery is a potent tool for converting cells into bioreactors to 
produce therapeutic proteins, options for localizing the viral particles to PEG scaffolds are limited. 
Cationic peptides were investigated and phage display was utilized to identify lentivirus-specific 
peptides. 
Chapter 5 addressed challenges presented by the immune system by employing PLGA 
scaffolds decorated with FasL, an immunoregulatory protein, to create an immunoprivileged 
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microenvironment that protects allogeneic cell transplants. Together, these methods will control 
the scaffold microenvironment to create conditions conducive to the survival of insulin-















CHAPTER 2. Background 
 
2.1 Introduction  
 Type 1 diabetes is a metabolic disease characterized by insufficient insulin production 
and subsequently high blood glucose concentrations (hyperglycemia). Insulin functions as a 
peptide hormone that is secreted from β cells in the pancreas and stimulates the uptake of 
glucose from the bloodstream into muscle, liver, and fat cells. Although the cause of disease 
onset is not known, it is suspected that a combination of genetic and environmental factors 
play a role in initiating the T-cell mediated autoimmune response to β cells. This theory is 
supported by the frequency of patients with the disease and specific HLA haplotypes that are 
associated with autoimmune regulation [8].  
Although exogenous administration of insulin has vastly improved the prognosis for 
patients suffering from diabetes, it has become apparent that proper glycemic control is 
essential to prevent secondary microvascular complications (diabetic nephropathy, retinopathy, 
and neuropathy) and macrovascular complications (coronary artery disease, peripheral artery 
disease, and strokes) [9, 10]. Insulin pumps and continuous glucose monitors were a significant 
step forward in modulating glucose control and have made considerable advancements in 
recent years in approximating the pancreas. Despite advances in these technologies, 
maintaining proper glucose levels remains a challenge for many patients [11]. Long term 
imperfections in glycemic control lead to complications. Islet transplants reduces severe 
fluctuations. Furthermore, production of C-peptide, a byproduct of endogenous insulin 
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production, plays a role in minimizing nephropathy and improves peripheral nerve function 
[12]. 
A cell-based solution is preferable, as it can provide improved feedback regulation and 
endogenously produce insulin. Whole organ pancreas transplants have been performed since 
1966 and have seen considerable success, but the process is considered invasive, technically 
challenging, and requires management of the pancreatic exocrine secretions. Islet transplants 
offer more flexibility and, similar to whole pancreas transplants, can reverse many of the 
secondary complications. Notably, the technique known as the Edmonton Protocol has shown 
promising results in which islets from several donors are implanted into the hepatic portal vein 
and administered a life-long regimen of immunosuppressants. Following the procedure, 44% of 
the patients were insulin independent with adequate glycemic control three years after the final 
transplantation [13]. However, this approach faces serious short and long-term challenges as 
intraportally transplanted islets are directly exposed to blood that triggers an instant blood-
mediated inflammatory reaction (IBMIR), a pathological nonspecific inflammatory response that 
results in severe islet damage and significant graft loss. Islets introduced into the portal vein must 
also remodel and vascularize their microenvironment as the low oxygen tension in the liver 
results in ischemia-induced cell loss [14]. Together, the inflammatory response can account for 
more than 60-80% of islet loss days post-transplant within a matter of hours to days [15].  
Furthermore, IMBIR promotes a pro-inflammatory environment which then leads to 
activation of the adaptive immune system in the form of activated T- and B-cells that causes 
additional injury to islets [16]. The combined effects of the auto- and alloimmune response 
require the administration of a lifelong regimen of immunosuppressants that leaves the patient 
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vulnerable to infection and cancer [17]. Despite refinements in specific immunosuppressive 
drugs and dosage used in islet transplantation [18, 19], these challenges have resulted in only 
15% of cases still euglycemic after nine years [20]. Furthermore, the number of islets required 
for the procedure is unsustainable for widespread use, as the harmful effects of IBMIR 
necessitate the need for multiple transfusions from two to four donors into a single recipient [21, 
22]. 
2.2 Alternative transplant sites 
Although the liver has historically been a favored islet infusion site due to its ease of 
access, the inflammatory effects from IBMIR and hepatic tissue ischemia make it a suboptimal 
location [23]. Furthermore, the liver cannot be extensively modified since it carries out important 
functions such as blood detoxification and aids in digestion. In order to avoid many of these 
complications, an alternative transplant site must be established in which the environment 
around the islets can be carefully modulated. Qualities that are considered desirable for islet 
transplants include sufficient vascularization for the high oxygen requirement of the islets, 
creation of a microenvironment that prevents early islet loss, minimally invasive procedure, and 
easily retrievable transplants for follow-up studies. Of particular note, revascularization is 
essential not only for the high oxygen requirements of the islets, but also to allow for rapid 
response to fluctuations in the blood glucose concentration [24]. Furthermore, the islet isolation 
process puts stress on the islets, thus highlighting the importance of rapid revascularization in 
the post-transplant environment. Otherwise, poor vascularization leads to islet dysfunction and 
impairs metabolic function [25].  
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Besides the intravascular portal vein, extravascular sites (pancreas [26], omentum [27], 
kidney capsule [28], and gastric submucosa [29]) and immunoprivileged sites (anterior chamber 
of the eye [30] and testis [31]) have been considered. The pancreas is the native tissue site of 
islets and is expected to be an ideal environment for islet transplantation. Indeed, in studies 
utilizing mouse models that compared intraportal to intrapancreatic transplants, the pancreas 
demonstrated better insulin production and control, improved glucose oxidation, and higher 
(pro)insulin biosynthesis [25]. These results also highlighted the challenges faced with intraportal 
transplants in which islets are chronically exposed to high glucose levels produced by the 
surrounding hepatocytes in addition to functioning in environment that is the site of blood 
detoxification. Islets still experience physiological changes when transplanted back into the 
pancreas, as suggested by evidence showing they are slightly hypoglycemic and undergo some 
gene expression changes [25, 32]. Even though intrapancreatic transplants have provide a viable 
microenvironment that requires fewer islets to reverse hyperglycemia than other sites like the 
portal vein or the kidney capsule and provide efficient glycemic control [33], many of these 
studies have been performed in syngeneic models that do not take into account the immune 
response. Furthermore, the surgery site is technically challenging as it risks acute complications 
from digestive enzyme leakage and it is theorized that the autoimmune response from T cells will 
respond quicker [34]. As such, it is not considered a viable option for clinical applications.  
The omentum is a layer of peritoneum that surrounds abdominal organs and provides 
several attractive properties, including its good vascularization, portal drainage, and has been 
shown to safely handle large transplant volumes in large animals models [35]. Previous studies 
in rats and dogs that utilized an omental pouch successfully restored euglycemia but required an 
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increased graft volume when compared to intraportally transplanted islets. [36, 37].The 
omentum in mice differs significantly from humans in that it is considerably smaller and poorly 
vascularized. Therefore, studies with mice wishing to translate to the human omentum often 
utilize the epididymal fat pad which is well vascularized and is similarly easily accessible and 
removed from the animal without disrupting any vital bodily functions [38]. This site has also 
been the site of numerous studies implanting biomaterial scaffolds to further modify the 
microenvironment [39-41]. However, the epididymal fat pad differs from the human omentum 
in that it lacks portal drainage. Overall, the omentum offers sustained insulin control due to its 
high vasculature and pro-angiogenesis cytokines [42], but the requirement for large islet number 
necessitates the need for additional long-term data. 
 A widely used option is the renal subcapsular site (also known as the kidney capsule) 
which is frequently applied in murine models. Compared to the native tissue in the pancreas, the 
renal capsule has relatively poor blood supply (15 mmHg O2) and does not provide an oxygen-
rich environment required for maximal islet viability (40 mmHg O2) [43]. However, the capsule in 
mice is readily accessible and has been demonstrated to reverse chemically-induced diabetes 
within a few days after transplants [44]. It is also considered an attractive site as it requires less 
islet volume when compared to intraportal transplants (250 islets in the subcapsular site versus 
700 islets in the portal site [45, 46]) and the ease of retrieval via a simple nephrectomy [47]. 
Unfortunately, the surgery in humans is more difficult and access is much more invasive. Finally, 
the space available for transplanting islets severely limits its use beyond a tool in murine models. 
 The gastric submucosa is an appealing option as it is a natural entry site for glucose into 
the body which makes it a strong candidate for islet transplants as it allows for rapid response to 
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glucose stimuli. It consists of a dense network of vasculature, lymphatics, and connective tissue 
that makes it a suitable environment for islets and is available via endoscopy [48]. Because of its 
relative ease of access, follow-up analysis is straightforward. Although it has shown efficacy in 
rat, hamster, and pig models with better glycemic control than the kidney capsule, there has not 
been any head to head study with portal vein transplants [29, 49, 50]. As such, it has not yet been 
translated into the clinical studies and further studies must be completed before it can be 
considered a viable alternative to portal vein transfusion.  
In regards to immunoprivileged transplant sites, the anterior chamber of the eye and the 
testis are commonly studied sites due to their ability to promote engraftment while not requiring 
the use of immunosuppressants. The ocular microenvironment’s immune privileged status is 
well-characterized and is maintained by a blood barrier along with immunoregulatory and 
immunosuppressive molecules [51]. In vivo characterization of the anterior eye chamber using 
laser-scanning microscopy has shown allogeneic islet transplants engraft into the iris, became 
vascularized, responded to glucose stimuli, and reversed chemically-induced diabetes in all mice 
within two weeks [52]. In this study, mice were euglycemic for over 200 days until transplant 
removal. More long-term studies have demonstrated survival of α, β, and δ-cells after 1.5 years, 
although function was not assessed [53], and the procedure has been proven safe in non-human 
primates without causing vision problems or other adverse effects [30].  
The testes have a developed immune privileged mechanisms similar to the eye, but with 
its own unique features. The Sertoli cells provide a physical blood barrier to isolate germ cells 
from the immune system along with a host of immunoregulatory compounds that suppress pro-
inflammatory responses from the immune cells to maintain the immunoprotective environment. 
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Allographs [54] and even xenographs [55] into the testes have been proven successful in delaying 
rejection and it has been shown that graphs generate much less CD8(+) T cells while inducing 
increased numbers of CD4(+)CD25(+) regulatory T cells when compared to subrenal transplants 
[56]. Interestingly, Sertoli cells have been transplanted under the renal capsule with allogeneic 
islets and slightly delayed rejection by 15 days even when no immunosuppression was used [57]. 
Despite the success that these immunoprivileged sites have seen in animal models, these sites 
are generally not considered clinically relevant due to the small size of their organs. 
2.3 Biomaterial scaffolds 
As no transplant site is clearly superior and meets all the requirements for islet 
transplantation, an alternative site can be engineered. Scaffolds are biomaterial devices that 
provide chemical and physical cues to control the microenvironment and subsequently alter 
cellular behavior. Cells sense and respond to physical cues on the scaffold surface via integrins 
and other cell adhesion molecules which integrate these signals into cellular processes and gene 
expression [58]. Scaffolds also serve as a platform for controlled release of chemical cues such as 
anti-inflammatory drugs, growth factors, or inhibitors [59-61]. Three dimensional scaffolds can 
even be engineered to spatially regulate drug release in the microenvironment to fulfill specific 
functions [62, 63]. In addition to providing signals, the scaffold is space filling and provides an 
environment that resists compression and tension to create an environment in a part of the body 
that would normally not be possible [64]. The porous nature of scaffolds is essential to promote 
cellular infiltration, nutrient transfer, and vascularization to increase cell survival. In the context 
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of transplanting ß cells, vascularization is required for sensing and release of insulin in addition 
to efficient nutrient and oxygen transfer.  
Material selection plays a central role in scaffold creation. Scaffolds are formed from 
natural materials (e.g. collagen, fibrin, or alginate) or synthetic polymers (e.g. poly(lactic-co-
glycolic acid) (PLGA), polycaprolactone (PCL), or polyethylene glycol (PEG)). Natural scaffolds 
possess intrinsic signals such as cell binding domains and cell-triggered degradation [65, 66]. 
However, these materials may elicit immunogenic responses due to purification concerns [67].  
Synthetic materials offer greater control as they consist of well-defined polymers and their 
mechanical properties can be engineered for specific applications.  
Alternatively, materials can be classified based on their mechanical properties, with 
hydrogels being of especial interest for tissue engineering. Hydrogels are a promising platform 
for therapeutic applications due to their tissue-like mechanical properties and ease of cell 
encapsulation.  Hydrogels are typically categorized as either natural (e.g. fibrin, alginate, and 
collagen) or synthetic (e.g. PEG and poly(hydroxyethyl methacrylate) (pHEMA)).  Whereas 
natural hydrogels have established interactions with cells, synthetic hydrogels allow for more 
precise interactions and can be modified with proteolytically degradable linkers to target 
specific cell populations [68].  To provide dynamic control of cell integration and release of 
encapsulated factors, both natural and synthetic hydrogels have been engineered to degrade in 
response to pH or temperature [69, 70]. Of particular interest are PEG hydrogels, which is a 
versatile material that can be easily functionalized with peptides and proteins for localized 
delivery, or chemical cues can be encapsulated and released via diffusion. Degradation can be 
controlled by incorporating proteolytically degradable peptide linkers. Furthermore, PEG is a 
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biologically inert material and known to have a low immunogenic response [71]. By reducing 
the response of the innate immune system to the scaffold, activation of the adaptive immune 
system can be minimized, thus reducing the risk of transplant rejection [72].  
2.4 Viral delivery of soluble factors 
Delivery of soluble factors to the local environment of the transplanted islets can promote 
survival, vascularization, and growth. Systemic delivery frequently results in off-target effects and 
requires higher doses. The localized delivery of gene therapy vectors represents a versatile 
method to promote the sustained expression of inductive factors in numerous applications of 
regenerative medicine. The delivery of gene therapy vectors is considered versatile as the 
nucleotide sequence can readily be exchanged to express one or more factors using a single 
delivery system [73, 74]. Both non-viral and viral vectors can promote prolonged transgene 
expression, with non-viral vectors generally considered to be safer as they generally do not 
integrate into the host chromosome, yet have significantly lower levels of transgene expression 
than viral vectors. Viral vectors have evolved mechanisms for effectively transducing target cells 
and thus provide the greatest levels of expression.  
Of particular interest, lentiviral vectors are well-suited for clinical gene delivery 
applications due to their capacity for stable, long-term integration by inserting its genes into the 
host genome [75], and  have recently received approval in a Phase 2/3 clinical trial [76].  Lentiviral 
tropism has been greatly expanded by pseudotyping its envelope with the glycoprotein of the 
vesicular stomatitis virus (VSV-G) which not only allows for the virus to infect a wide range of cell 
types, but also deliver genes to both dividing and non-dividing cells [77-80].  Additionally, their 
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ease of production, relatively low immunogenic profile [81], and large genetic payload make 
them excellent candidates as gene delivery vectors.  Advances in lentiviral vector design have 
yielded improvements in their safety and efficiency over early generation viruses, and have been 
effectively used in clinical research to treat a variety of diseases including immune disorders [82], 
brain disease [83], and retinal dystrophy [84, 85].   
Current methods to localize lentivirus to scaffolds have applied a variety of methods that 
take advantage of properties of the virus and scaffold material.  A simple approach is the direct 
adsorption of the virus to a charged polymer’s surface like poly(1,8-octanediol citrate) (POC) and 
poly(glycerol-sebacate) (PGS) which utilize electrostatic interactions between the viral particle 
and negatively charged carboxyl groups on the materials’ surface [86].  Similarly, positively 
charged hydroxyapatite nanoparticles have been incorporated into poly(lactide-co-glycoolic acid) 
(PLGA) scaffolds and demonstrated a 10-fold increase in transgene expression and increased the 
half-life of the virus by 17% [87, 88].  However, these approaches rely on electrostatic 
interactions, which are subject to non-specific adsorption by unwanted proteins, and are 
material-specific.  Alternatively, methods that utilize specific interactions avoid these off-target 
effects.  Phosphatidylserine (PS), a phospholipid, has been implicated in lentiviral binding to cell 
membranes and has been incorporated into PLGA microspheres to enhance localized lentiviral 
delivery [89].  Not only did the PS prolong the expression of the reporter gene, but its specific 
binding capability was demonstrated by lack of non-specific adenovirus binding.  Another 
approach is the modification of the lentiviral coat proteins to enable covalent crosslinking with 
fibrin hydrogels, which allows for release of lentiviral particles as the hydrogel degrades [90].  
However, these specific-binding approaches still face significant challenges.  The incorporation 
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of PS into other scaffold materials is difficult and its role in signaling apoptosis may make it 
undesirable for further in vivo applications.  Although the modification of the lentiviral coat 
protein provides excellent specificity for localization to the fibrin hydrogel, the virus is covalently 
cross linked to the material.  Due to the half-life of the lentivirus being only 8-9 hours at 37oC, 
most of the virus will deactivate before coming in contact with cells. 
2.5 Immunoregulation 
Although considerable progress has been made with transplanting islets in biomaterial 
scaffolds, much of the success has occurred in syngeneic transplants with chemically-induced 
diabetes. A critical challenge that needs to be addressed is the immune system’s role in the 
destruction of insulin-producing cells. T1D is mediated by CD4 positive T cells that react to 
antigens specific to ß cells [91]. In addition to recurrence of the original autoimmune disease, the 
allogeneic response to transplanted tissue represents a significant hurdle. Tissue transplants are 
rejected via the adaptive immune system which senses mismatched MHC’s and induces a 
subsequent inflammatory cascade. The Edmonton protocol’s principle innovation was the special 
combination of immunosuppressants to limit immune-mediated islet destruction, but the lifelong 
systemic administration results in undesirable side effects. Complications such as lymphopenia 
and expansion of autoreactive CD8 positive T cells motivate the need for a targeted approach 
that locally modulates the immune system [92].  
In an effort to isolate islets from the immune system, groups have tried to encapsulate 
islets in a semi-permeable membrane that physically shields insulin producing cells from the 
immune system while still allowing for oxygen, nutrients, and protein transport [93, 94]. 
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However, mass transport limitations, insufficient immunoprotection, and the inability to 
reproduce results in large animal models have limited use of micro- or macro-encapsulating 
technologies. Encapsulated islets inherently limit vascularization and subsequently delays the 
response of β cells to fluctuations in blood glucose concentrations. Many encapsulating systems 
suffer graft failure as a result of fibrosis around capsules [95]. Finally, these membranes do not 
limit the transport of inflammatory cytokines and other immunoreactive molecules [96, 97].  
An alternative approach to achieve localized immunosuppression is the controlled release 
of immunoregulatory proteins from biomaterial scaffolds. Due to the central role of T-cells in 
allogeneic rejection, FasL is a viable option due to its role as a major regulator of T cell 
homeostasis. After antigen clearance by CD 8 positive T cells, deletion of effector cells by FasL-
mediated apoptosis occurs [98]. FasL works by binding the Fas receptor (FasR) which forms the 
death-inducing signaling complex (DISC) which is composed of Fas-associated protein with death 
domain (FADD) and caspase 8 which subsequently transduces a downstream signal cascade that 
leads to cell death. The challenge with protein or drug delivery is that rejection is only delayed 
and will fail as soon as the compounds are depleted from the local environment unless tolerance 
is induced.  
Early studies in inducing tolerance demonstrated that development of autoimmune 
diabetes in NOD mice can be prevented and reversed with bone marrow (BM) transplants from 
non-autoimmune allogeneic sources and subsequently inducing donor-specific tolerance [99, 
100]. However, this approach suffers from graft vs host disease (GvHD) in which T cells 
transplanted with the BM attack the host. This approach has been refined to use hematopoietic 
stem cells (HSC’s) [101]. Tolerance can also be induced by treating donor splenocytes with 1-
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ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) which target recipient antigen presenting 








CHAPTER 3. Evaluation of Encapsulating and Microporous Hydrogel Scaffold 
Designs on Islet Engraftment in Rodent Models of Diabetes 
 
3.1 Introduction 
Islet transplantation is therapy which can mimic normal pancreas physiology and aid in 
maintenance of normoglycemia [9]. However, this procedure is not widely employed in the clinic 
due to graft failure post-transplant, largely mediated by inflammatory factors and the host 
immune response. Upon injection into the hepatic portal vein, transplanted islets are subject to 
IBMIR, which can account for significant islet death within hours to days after the transplant [15]. 
Furthermore, IBMIR promotes a pro-inflammatory environment, which then leads to activation 
of adaptive immunity and additional islets loss [16]. Scaffold-based strategies have been 
successfully employed to create alternative transplant sites [103-105]. Previous work in our lab 
has made extensive use of PLGA scaffolds, but its material properties are dissimilar to tissue and 
the mechanical disparity can promote inflammation [106]. In contrast, PEG hydrogels are a 
versatile material ideally suited for tissue engineering due to its tissue-like mechanical properties, 
ease of functionalization, and controlled rate of degradation [107]. Furthermore, its 
macrostructure can be further modified to contain pores and channels to enhance cell infiltration 
and promote entrapment of viral or non-vectors [108].   
PEG-maleimide hydrogels were adapted into an encapsulating and microporous scaffold 
architecture using polydimethylsiloxane (PDMS) molds to easily and reproducibly fabricate the 
gels with matching dimensions. PEG functionalized with maleimide offers a fast and efficient 
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reactive group for functionalization [109]. PEG-acrylate, which is commonly used to form 
photopolymerized hydrogels, is prone to hydrolysis of conjugated peptides [110], whereas 
maleimide groups can form covalent bonds that are resistant to uncontrolled degradation [111]. 
Pores for cellular infiltration can be created by casting the PEG precursor around sacrificial 
particles followed by photocrosslinking of hydrogel. Photocrosslinked hydrogels are favorable 
because they quickly form at ambient conditions while providing spatial and temporal control, 
thus allowing for geometrically complex hydrogels to be formed with relative ease [112]. The 
particles are leached from the scaffold in an aqueous buffer, leaving behind a porous structure. 
This particle leaching process is advantageous compared to other porogen approaches such as 
freeze drying or gas foaming due to the ease of which pore size and porosity can be controlled 
[113]. Encapsulating hydrogels were formed utilizing Michael-type addition reactions to 
eliminate any concerns associated with free-radical polymerization affecting the viability of the 
cells. Initial studies employed a syngeneic transplant model in an extrahepatic site (i.e. 
epididymal fat pad) of diabetic mice to evaluate islet survival and function, and to characterize 
the innate immune response to the transplantation and surgical process. Subsequent studies 
employed allogeneic islet transplantation, with similar characterization of the islet function, and 
characterization of both the innate and adaptive response to the transplanted cells.  
Finally a method to locally deliver proteins from the PEG scaffolds was developed. In 
addition to mechanical cues provided by the scaffold, another method of modulating the 
microenvironment is controlled release of soluble compounds from the scaffold. There are a 
variety of delivery mechanisms such protein entrapment in the nanoporous PEG network [114], 
peptide affinity binding [115], or viral gene delivery [116]. Previous work in our lab has indicated 
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that proteins entrapped in the PEG rapidly diffuse out of the scaffold during the leaching step 
which results in insufficient protein delivery. Additionally, the high salt concentration used in the 
fabrication of the scaffold may damage any protein that is retained. We demonstrated that a 
PLGA disc loaded with protein and inserted inside of the porous PEG scaffolds was able to deliver 
therapeutically relevant amounts of protein. Herein, we used TGF-ß due to its ease of detection 
in in vitro and in vivo, in addition to its release being well characterized in PLGA scaffolds [117]. 
3.2 Materials and methods 
3.2.1 Encapsulated and microporous hydrogel fabrication  
Encapsulated hydrogels were formed by mixing PEG-maleimide (4-arm, 20kDa MW, 
JenKem Technology USA) and CGRGDS (CelTek Peptides) in HEPES Buffer (pH 7.2) to yield a final 
PEG concentration of 10% (wt/vol) and RGD concentration of 5 mM. The PEG-CGRDS solution 
was allow to react via Michael-Type addition for 5 minutes at room temperature and then stored 
on ice.  Next, the functionalized PEG precursor was added to sedimented islets in an Eppendorf 
tube (in approximately 6 μL of HBSS 1X media (Corning) supplemented with 10% FBS). The 
bottom of a disc-shaped PDMS mold (diameter = 5 mm, height = 1 mm) was covered with 3 μL of 
a non-degradable peptide crosslinker solution (GCYDKNDRGCYDKNDRCG, custom synthesis and 
purification by CelTek Peptides). The peptide contained tyrosine (Y) and asparagine (N) amino 
acids in the D-configuration to prevent cleavage from plasmin, which inhibits hydrogel 
degradation. The PEG precursor containing islets was added to the mold containing the YKNR 
solution and an additional 3 μL of YKNR was added on top for a final YKNR concentration of 9.6 
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mM. The hydrogel was incubated at 37C for 30 minutes to allow the crosslinking reaction to 
reach completion. Final gel volume was approximately 25 μL. 
Gelatin microspheres were formed by dissolving type A gelatin, bloom strength 300 
(Sigma), into ultrapure water heated to 80 oC for a final concentration of 10% (w/w). The gelatin 
solution was added dropwise into mineral oil heated to 80 oC and stirred at 500 rpm. The water-
oil emulsion was cooled using an ice jacket while maintaining a stir speed of 500 rpm for 1 hour. 
The ice jacket was removed and acetone was added while the stirring speed was maintained. 
Next, the stirring was stopped and the mineral oil and acetone were allowed to separate, 
followed by removal of the mineral oil. The acetone wash and mineral oil removal was repeated 
for a total of three times before all liquid was removed and the remaining gelatin microspheres 
were mixed by hand until all acetone evaporated. Particles were stored under dry inert gas until 
use. 
Microporous PEG hydrogels were fabricated by dissolving 20 kDa 4-arm PEG-maleimide 
(JenKem Technology USA) in HEPES buffer for a final concentration of 20% (wt/vol).  The 
photoinitiator, Irgacure 2959 (BASF) was dissolved in N-vinylpyrrolidone at a concentration of 
600 mg/mL and added to the PEG precursor solution for a final concentration of 1 wt%. For 
hydrogels utilizing NaCl as a porogen, NaCl was added to the PEG precursor to make a saturated 
solution. Forty milligrams of NaCl particles (average diameter = 250 µm) or gelatin microspheres 
were then added to a polydimethylsiloxane (PDMS) mold (diameter = 5 mm, height = 1 mm) and 
10 μL the saturated PEG solution was added. After irradiation with UV light, the porogen was 
leached from the scaffolds by incubating in ultrapure water overnight. Final gel volume was 
approximately 25 μL. 
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Non-porous PLGA discs containing TGF-β1 were fabricated as described in Liu, et al [117]. 
Briefly, 2 mg of PLGA microparticles and 2 µg of TGF-β1 were reconstituted in 100 μL of an 
aqueous 10 mg/mL D-mannitol solution and lyophilized. The PLGA-protein-mannitol powder was 
pressed in a 3 mm KBr pellet hand press (Pike Technologies) and gas-foamed at 800 psi under 
CO2 gas for eight hours using a previously described technique [118]. These discs were either 
placed on top of the encapsulated hydrogels or the microporous scaffold was formed around the 
disc.  
3.2.2 Islet isolation and transplantation 
For syngeneic studies, islets were isolated from healthy 10-12 week old male and female 
C57BL/6J mice (Jackson Laboratories) following standard islet isolation procedures. Male 
C57BL/6J recipient mice were between 14-18 weeks of age. For allogeneic transplants, female 
BALB/c (Jackson labs) islet donors and male C57BL/6J transplant recipients between 10-12 weeks 
were used. Four days prior to islet transplantation, recipient mice were injected with 220mg/kg 
of streptozotocin (Sigma) to chemically induce irreversible diabetes. Nonfasting blood glucose 
levels were taken using a OneTouch Basic Glucose Monitor (Aviva) and only those mice with a 
measurement of 300 mg/dL or greater on consecutive days (day before and day of transplant) 
were used as recipients. Normoglycemia was denoted as <200 mg/dL in syngeneic studies. All 
hydrogel scaffolds in syngeneic studies were loaded with 700 islet equivalents (IEQ). To load 
microporous hydrogels, islets were concentrated in 30 μL and applied to the top of a dehydrated 
hydrogel. Each mouse received one gel into the fat pad transplantation site. For allogeneic 
studies, 10-12 week old female BALB/c mice (Harlan Laboratories) were used as donors. 
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Normoglycemia was denoted as <250 mg/dL and mice received 1,300 IEQ for allogeneic 
transplant studies. Each mouse received one hydrogel implant into the fat pad. All studies were 
approved by the Northwestern University Animal Care and Use Committee. 
3.2.3 Intraperitoneal glucose tolerance test 
Intraperitoneal glucose tolerance tests (IPGTTs) were performed at 4 weeks post-
transplantation to assess the ability of the hydrogel materials to respond to glucose challenges. 
A D-glucose solution (250 mg/mL sterile PBS (-/-)) was created for injection. After a 3 hour fast 
period, 2 g/kg of D-glucose was injected intraperitoneally. Blood glucose levels were measured 
at baseline (before injection), 15, 30, 60, 90, 120, and 150 minutes after the glucose injection. 
3.2.4 Immunohistochemistry 
Snap-frozen histological sections were stained with primary antibodies guinea pig polyclonal anti-
swine insulin (Jackson Labs) and Hoechst (Invitrogen) at dilutions 1:250 and 1:2000, respectively. 
Secondary antibodies included Dylight donkey anti-guinea pig 488 (Jackson Labs) at a dilution of 
1:400.  
3.2.5 TGF-β1 in vitro release studies 
 Scaffolds were leached in 10 mL of water containing 1% BSA (Millipore), sterile filtered, 
for two 10 minute washes. Leached scaffolds were placed in a 24 well plate with 1 mL of media 
(DMEM supplemented with 10% FBS, 1% penicillin and streptomycin) and incubated at 37 oC. At 
days 1, 3, 7, 14, and 21 the supernatant was replaced with fresh media and the old media was 




3.3.1 Encapsulating and Microporous Hydrogel Fabrication 
Encapsulated hydrogels were formed by functionalizing 4-arm PEG maleimide with 5 mM 
CGRGDS and crosslinked in a PDMS mold, using a non-degradable, three-cysteine-containing 
crosslinking peptide (GCYKNRGCYKNRCG) (Fig. 3-1A). After 5 minutes at 37°C, gels were fully 
crosslinked and intact with no residual macromer (Fig. 3-2A). Resultant gels were 25 μL and 10% 
(wt/vol). Dimensions of the encapsulating gel were 5 mm in diameter and approximately 1 mm 
in height, adequate for implantation into the fat pad. Islet viability with these gelation conditions 
was confirmed in a previous study [41].  
To fabricate microporous hydrogels, 20 (w/v)% 4-arm PEG-maleimide (20,000 kDa) was 
dissolved in HEPES buffer and the cell adhesion peptide NH2-CGRGDS-Ac was conjugated to the 
PEG via Michael-type addition between the maleimide and the cysteine’s thiol group. Salt (NaCl) 
and gelatin were selected as porogens due to their nontoxic properties and their ability to be 
rapidly leached from the scaffold in mild conditions (Fig. 3-1B, C) [119, 120]. To prevent the salt 
porogen particles from dissolving in the aqueous environment prior to gelation, salt was added 
to the PEG precursor to make a saturated solution. Gelatin microspheres (size: 107±4 µm, n = 41, 
±SEM) or salt crystals (size: 274±12 µm, n = 41, ± SEM) were added to a polydimethylsiloxane 
(PDMS) mold followed by the PEG solution (Table 3-1, Fig. 3-2B, E). Hydrogels were cross linked 
with UV light and Irgacure-2959, a commercially available photoinitiator commonly used due to 
its relatively cytocompatible properties [121]. The scaffolds were incubated in ultrapure water at 
37oC for overnight to rapidly dissolve the porogen and leave a highly porous PEG scaffold (Fig. 3-





Figure 3-1. Fabrication of PEG-maleimide hydrogels. (A) Encapsulated hydrogels are formed by 
mixing the peptide cross linker GCYKNRGCYKNRCG with a PEG/islet solution in a PDMS mold. 
Cross linking is induced via Michael-type reaction between the thiols in the peptide and the 
maleimide groups on the PEG. (B) Microporous hydrogels are formed by packing gelatin particles 
into a PDMS mold and adding PEG. After initiating free-radical polymerization via UV light and 
the photoinitiator I-2959, the gelatin particles are leached out at 37 oC, leaving a porous hydrogel 
that can be seeded with islets. (C) Microporous hydrogels with salt pores are formed in a manner 
similar to the gelatin microspheres, but require the PEG precursor solution to be saturated with 
salt prior to being added to the salt-packed PDMS mold. After polymerization, the salt is quickly 








Figure 3-2. Encapsulating and microporous hydrogels for islet transplantation. (A) 10% (wt/vol) 
bulk PEG hydrogels were fabricated to encapsulate islets. (B) Gelatin particles (size = 107± 4 μm, 
n =41) were fabricated, incorporated into 20% PEG (wt/vol), and subsequently leached to form a 
(C-D) resultant hydrogel with a microporous architecture for islet seeding. Similarly, (E) salt 
particles (size = 274 ±12 μm, n = 41) were incorporated into 20% PEG (wt/vol) to form a (F-G) 
microporous gel for islet seeding. Scale bar:  1 mm (A, C, F), 100 μm (B), 200μm (D,E,G). Gels were 





Table 3-1. Particle size of gelatin and salt particles used as a porogen for microporous hydrogels. 




resulted in collapsible gels with insufficient integrity for islet seeding. The volume and dimensions 
of the microporous hydrogel were the same as the encapsulating hydrogels. Following swelling, 
encapsulating and microporous hydrogels were approximately 6.5 mm in diameter and 1.5 mm 
in height, a size still suitable for transplantation.   
3.3.2 Syngeneic islet transplants in encapsulating and microporous hydrogels 
The engraftment and function of encapsulated islets and islets seeded on microporous 
hydrogels were investigated by transplantation into the fat pad site of streptozotocin-induced 
diabetic mice. Initial studies were performed in a syngeneic model to confirm the hydrogel 
materials can support islet function in the absence of an immune response. Bulk, non-degradable 
encapsulating hydrogels with 700 islet equivalents (IEQ) reversed diabetes in recipient mice, and 
an average normoglycemic (<200 mg/dL) blood glucose level of 175±31 mg/dL (n=3, ± SEM) was 
achieved by day 17 (Fig. 3-3A). Normoglycemic readings were recorded for all recipient mice at 
day 21 (140±6 mg/dL) and mice remained normoglycemic until the end of the 2-month study. 
Encapsulating hydrogels were removed (indicated with a black arrow) at day 62 and recipient 
mice reverted to hyperglycemic state within 2-4 days post-removal, which confirmed glycemic 
control is due to the hydrogel graft and not any remaining endogenous islets post-streptozotocin 
injection.  
A pilot study of the gelatin-leached microporous hydrogels were seeded with 700 IEQ 
demonstrated the ability to reverse diabetes by day 10. Interestingly the blood glucose levels 
spiked between days 87 and 100 for unknown reasons. Following removal of the hydrogel at day 
108, mice immediately reverted to hyperglycemia. Gelatin-leached hydrogels were more 
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extensively explored in Fig. 3-3C in which the microporous hydrogels were seeded with 200 islets, 
similar to previous studies in PLGA scaffolds [104, 122]. The average normoglycemic blood 
glucose level was 173±10 mg/dL (n=4, ± SEM) and all mice reversed diabetes by day 9. For 
comparison, a microporous PLGA scaffold was also seeded with 200 islets and restored 
euglycemia by day 7, two days earlier than the microporous hydrogel. Both scaffolds reverted to 
hyperglycemia within 2-4 days after graft removal.  
Salt-leached, microporous hydrogels seeded with 700 IEQ displayed an average 
normoglycemic blood glucose level of 190±20 mg/dL (n=5 pre-graft removal, n=4 post-graft 
removal, ± SEM) by day 15 post-transplant (Fig. 3-3D). Normal blood glucose levels were recorded 
for all recipient mice at day 20 (139±15 mg/dL). Upon removal of the transplanted microporous 
hydrogel at day 30, mice reverted to a hyperglycemic state within 2-4 days. Engraftment rates 
did not differ between encapsulating and microporous hydrogels containing 700 IEQ, as 
consistent normoglycemia was achieved approximately at 3 weeks post-transplant in both 
experimental groups. Collectively, these syngeneic transplant studies confirm the feasibility of 
non-degradable, encapsulating and microporous PEG hydrogels to support islet function post-
transplant in the fat pad transplant site.  
An intraperitoneal glucose tolerance test (IPGTT) was performed on mice that received 
hydrogels to investigate glucose responsiveness. The blood glucose levels of diabetic recipient 
mice with encapsulating hydrogels peaked at 30 minutes post-injection of glucose, versus control 
mice which peaked at 15 minutes post-injection (Fig. 3-4A). At 60 minute time points, blood 
glucose levels mice decreased toward normoglycemia in both groups. Normoglycemic levels 







Figure 3-3. Blood glucose monitoring post-transplant with hydrogel materials in fat pad 
transplantation site of diabetic mice. (A) Bulk, non-degradable encapsulating hydrogels with 700 
IEQ reversed diabetes in recipient mice, and approached normoglycemic levels by Day 12 (<200 
mg/dL), with consistent normoglycemia achieved after Day 17 (n=3, ± SEM).  (B) A gelatin-
leached, microporous hydrogel seeded with 700 IEQ (400 islets) reversed diabetes in a recipient 
mouse by Day 10 and displayed long-term function until graft removal at Day 106 (n=1, ± SEM). 
(C) Gelatin-leached, microporous hydrogels seeded with 200 islets reversed diabetes in recipient 
mice by Day 9 (n=4, ± SEM). Mice receiving a PLGA scaffold, used an internal control due to 
success in previous studies, reversed a few days earlier, by Day 7 (n=1). (D) Salt-leached, 
microporous hydrogels seeded with 700 IEQ displayed normoglycemic levels as early as Day 1 
post-transplant, and consistently maintained normoglycemia after Day 15 (n=5 pre-graft 
removal, n=4 post-graft removal, ± SEM). Recipient mice in all groups reverted to a diabetic state 




mg/dL) (n=5, ± SEM) and control group (187±4 mg/dL) (n=4, ± SEM), respectively. Blood glucose 
levels remained stabilized for the remainder of time points. Area under the curve indicated 
statistical significance at 30 minute (p=0.0061), 60 minute (p=0.0007), and 90 minute time points 
(p=0.0005) between the encapsulating and control group. Glucose tolerance tests were also 
performed on diabetic mice which received microporous hydrogels (gelatin leached n=4 ± SEM, 
salt leached n=5 ± SEM) (Fig. 3-4B, C). In both of the hydrogel groups and the control group (n=5± 
SEM), the blood glucose levels peaked at 15 minutes post-injection of glucose. At 30 minutes, 
blood glucose levels in mice decreased toward normoglycemia in all groups. At 60 minutes, the 
microporous gel (153±14 mg/dL) and control group (150±18 mg/dL) both achieved 
normoglycemic levels and their blood glucose remained normoglycemic for the remainder of 
time points. For comparison, glucose tolerance of a PLGA microporous scaffold was also included, 
which followed identical trends to the hydrogels. Area under the curve indicated no statistical 
significance at any time point between the microporous hydrogels and controls. The glucose 
challenge results demonstrate recipient mice with microporous hydrogels containing 
transplanted islets can respond to a glucose load in a similar manner to mice with native 
pancreata. However, a slight delay in achieving normal blood glucose levels is observed in 
recipient mice with encapsulating hydrogels. Similar findings for this delay have been reported 
for hydrogels containing encapsulated islets in a recent study [41]. 
3.3.3 Histological Analysis of Hydrogel Explants from Syngeneic Transplants 
Hydrogel materials remained intact and well-secured in the highly vascular fat pad 






Figure 3-4. Glucose responsiveness of microporous hydrogels. (A) Encapsulated hydrogels with 
700 IEQ (n=5, ± SEM) achieved normoglycemia (<200 mg/dL) 120 minutes post-glucose injection. 
In contrast, (B) mice receiving gelatin-leached, microporous hydrogels with 200 islets (n=4, ± 
SEM), a PLGA scaffold with 200 islets (n=1), or (C) salt-leached, microporous scaffolds with 700 
IEQ (n=5, ± SEM) achieved normoglycemia 60 minutes post-glucose injection, similarly to control 
mice with native pancreata. IPGTT performed at Day 32 (A), and Day 30 (B) post-transplant. 
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and a Hoechst nuclear counterstain to confirm their functionality post-encapsulation in vivo. 
Insulin-positive islets were retained in and identified in implanted both gelatin leached and salt 
leached microporous hydrogels at day 32 and 30 post-transplant, respectively (Fig. 3-5A-C). 
Histological analysis of encapsulated hydrogels will be completed in the near future. These results 
indicate islets seeded on PEG hydrogels were able to maintain their morphology, function, and 
engraft in the fat pad transplant site. 
3.3.4 Allogeneic Islet Transplants in Encapsulating and Microporous Hydrogels  
 Encapsulating hydrogels containing 1500 IEQ islets from BALB/c donors were 
transplanted into C57/BL6 diabetic recipient mice (n=4) to evaluate graft function (Fig. 3-6A). For 
the first 1-2 days post-transplantation, blood glucose levels decreased to normoglycemic levels, 
typically indicative of some transplanted islet loss. After day 3, the mice returned to 
hyperglycemia. An additional study was performed and the islet loading was increased to 3000 
IEQ (n=2) which lead to extended graft function of up to two weeks, but still failed to provide 
protection from the immune response (Fig. 3-6A). This indicates that encapsulation is not 
sufficient to prevent graft rejection. Allogeneic studies involving microporous hydrogels focused 
on utilizing salt as a porogen, as the syngeneic data did not indicate any significant difference 
between gelatin and salt porogens, and salt was considered more easily translated into the 
clinical setting. Although microporous hydrogels, which offer no inherent protection against an 
immune response, failed to achieve normoglycemia (Fig. 3-6B), one mouse did maintain 









Figure 3-5. Insulin-positive islets confirmed in microporous hydrogels (A-B) Insulin-positive islets 
were identified in gelatin-leached, microporous scaffolds removed at Day 32 and (C) salt-leached, 
microporous scaffolds removed at Day 30 (Scale bar: 100 μm). (D) Explanted salt-leached 
microporous hydrogel 1 month post-transplant. Histology for encapsulated hydrogels will be 








Figure 3-6. Allogeneic transplants failed to engraft before rejection. (A) Encapsulating hydrogels 
with 500 (n=4,± SEM) or 1,000 islets (n = 2, ± SEM) are unable to maintain normal blood glucose 
levels more than 2 weeks post-transplant, indicating encapsulation alone is not sufficient to 
prevent graft rejection. (B) With the exception of one mouse (blue line), salt-leached 





3.3.5 PEG hydrogels create a microenvironment conducive to islet survival 
Localized release of soluble factors from the scaffold can enhance the microenvironment 
and combat nonspecific inflammation at early stages of the transplant. Previous reports have 
demonstrated efficacy of the relatively simple technique of delivering proteins from a small PLGA 
disc loaded with protein [117, 123]. TGF-β1 was selected, as it is therapeutically relevant in 
nanogram quantities, thus making protein delivery easily detected. It inhibits inflammatory 
aspects of the immune system and stimulates regulatory T cell production, an important 
component of allogeneic tolerance [124, 125]. 
Non-porous PLGA inner layer scaffolds containing TGF-ß were formed by pressing PLGA 
microparticles with lyophilized protein and mannitol into a disc then CO2 foamed. The 
microporous hydrogel was formed around the inner layer by packing the PEG and salt mixture 
with the PLGA disc in a PDMS mold and cross linked. After leaching the salt, scaffolds were 
disinfected with ethanol and loaded with cells (Fig. 3-7D-F). Encapsulated hydrogels were simply 
implanted with the PLGA disc pressed between the adipose tissue and the scaffold (Fig. 3-7C). 
Prior to in vivo experiments, the release profile of protein from the scaffold was characterized by 
incubating the scaffolds in media for 30 days and the supernatant was periodically collected and 
replaced with fresh media. Eluted TGF-β1 was quantified with an ELISA and demonstrated that 
60% of the loaded protein is lost during the salt leaching step (Fig. 3-7A). Of the remaining 
protein, 60% was released by day 1 and 95% was released by day 7 (Fig 5-7B).  
Next, studies were performed in an allogeneic model to directly compare islet 
engraftment in encapsulating and microporous hydrogels, with or without TGF-β1 delivery, and 









Figure 3-7. Transforming growth factor-β1 (TGF-β1) in vitro release from PLGA scaffolds and 
incorporation into hydrogel materials. (A) A cumulative release of 0.66 µg was determined from 
PLGA disc loaded with 2 µg of TGF-β1.  (B) More than 80 % of total protein was released by Day 
3 (n = 5, ± SEM). (C) For encapsulating hydrogel transplants, a PLGA disc containing 2 µg of was 
placed on top of the hydrogel and wrapped in the fat pad. (D) For microporous hydrogels, the 
PLGA disc containing 2 µg was incorporated into the middle of the hydrogel. (E) Cross-section 
view of PLGA scaffold in microporous hydrogel. (F) Islets seeded on a microporous scaffold. A 
representative islet is indicated with a white arrow. 
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glucose >250 mg/dL in this study. Mice receiving encapsulating hydrogels with 1300 islets without 
TGF-β1 delivery were not able to maintain graft function and rejected after 2 weeks post-
transplant (Fig. 3-8A). Encapsulation and TGF-β1 delivery delayed rejection to day 24, compared 
to day 12 TGF-β1, which is a similar rejection timeframe to a microporous PLGA scaffold loaded 
with TGF-β1 [117]. A pilot study with microporous hydrogels loaded with TGF-β1 and 1300 IEQ 
demonstrated potential efficacy in which mice with TGF-β1 exhibited euglycemia by day 6 (Fig. 
3-8B). Scaffolds were removed at day 7 for immune cell analysis via flow cytometry, but no 
significant difference between the innate or adaptive immune cell populations was detected 
(data not shown). This time point was selected due to graft rejection typically occurring around 
day 10, and thus populations at day 7 may provide insight into local immune cell populations 
dampened by TGF-β1 delivery.  
3.4 Discussion 
In this study, we examined the utility of encapsulating and microporous PEG-based 
hydrogels for islet transplantation into the fat pad transplantation site in order to engineer an 
environment conducive to islet survival. Furthermore, this work offered the opportunity to study 
two unique scaffolds designs with the same material, allowing for a comparison to be made based 
on scaffold architecture. An important consideration in the development of biomaterial scaffolds 
is the ability to retrieve them for further studies without harming the host. Thus, non-degradable 
PEG scaffolds were developed for implantation into the epididymal fat pad to allow for 
straightforward recovery for further morphological analysis. Encapsulated islets are frequently 







Figure 3-8. Allogeneic graft function of scaffolds with TGF-β1 (A) Encapsulating hydrogels 
combined with TGF-β1 delivery delays rejection until Day 24 compared to rejection at Day 12 
without TGF-β1 (n = 2 per group, ± SEM). Rejection is denoted as two consecutive days of blood 
glucose >250 mg/dL. (B) Graft Function 7-days post-transplant in salt-leached microporous 
hydrogels. - TGF-β1 condition (n=2, ± SEM), + TGF-β1 condition (n=4, ± SEM). At day 7, the 
microporous hydrogels were removed for flow cytometry.  
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subcutaneously, or under the renal capsule, making recovery challenging [126]. By comparison, 
the macroencapsulated hydrogels and integrated host tissue was be easily removed from the 
epididymal fat pad for further analysis.  
Microporous PEG hydrogels, comparable in design to PLGA scaffolds [104], allowed for 
rapid cellular infiltration and engraftment, a critical requirement for successful islet transplants. 
The average pore size of these microporous scaffolds was 107 µm and 274 µm for the gelatin- 
and salt-leached hydrogels, respectively. The minimum required pore size for vascularization has 
been determined to be 30 to 40 µm to facilitate endothelial cell entrance [127, 128], and 160 to 
270 is suggested as ideal for hydrogels [129]. The difference in porogen not only affects pore size, 
but also the pore shape, as the gelatin microparticles are spherical whereas the salt grains are 
cuboidal. The gelatin contacts other spheres at points whereas the salt contacts at faces, which 
may affect pore interconnectivity. Despite these difference, both appear to be interconnected 
and tissue infiltrated throughout both of them by day 30. In regards to ease of fabrication, the 
gelatin-leached hydrogels were more straightforward, as the gelatin microparticles are not 
soluble in water at room temperature but can be dissolved at 37 oC, whereas the salt porogen 
requires a saturated salt/PEG solution which introduces solubility concerns. To fabricate clinically 
viable gelatin-leached hydrogels, the manufacturing process would need to be modified to meet 
Good Manufacturing Process (GMP) standards due to the use of mineral oil and porcine gelatin.   
Normoglycemia in the syngeneic mouse model was achieved in both microporous 
hydrogels by day 15 and the encapsulated at day 21 post-transplant. Glucose responsiveness of 
islets seeded in microporous hydrogels was confirmed via an intraperitoneal glucose tolerance, 
with normoglycemic levels achieved by 60 minutes, identical to the nondiabetic control mice. 
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Restoration of normoglycemia post-transplant and in the glucose challenge was observed in a 
similar, if not earlier timeframe, than other rodent studies that have used natural or synthetic 
hydrogels for islet transplantation in vascularized sites [27, 130]. In contrast, the encapsulating 
hydrogels response to the glucose challenge was slower than the microporous and control mice 
and peaked at the later time point of 30 minutes. Similarly, the glucose readings at the 60 and 90 
minute time points were significantly different from the control mice (p≤0.05), and appeared to 
lag behind the control’s glucose response by approximately 30 minutes at these times. Whereas 
the microporous PEG and controls reached a maximum blood glucose of 300-350 mg/dL, the 
encapsulated reached a maximum of 450 mg/dL. This delayed responsiveness was expected due 
to the time needed for glucose and insulin to diffuse across the PEG barrier. It is also worth 
mentioning that the nondiabetic control mice for the microporous hydrogels were very similar 
whereas the encapsulated control was noticeably higher. This may be accounted by the fact that 
the microporous studies were completed at Northwestern University in Chicago, IL, while the 
encapsulated studies were done at the University of Michigan in Ann Arbor, MI. 
In the allogeneic model, we hypothesized rejection may be delayed with the barrier 
provided by the non-degradable, encapsulating hydrogel design. Preventing direct contact with 
immune cells has been shown in some cases to improve allogeneic islet engraftment, with the 
goal of eliminating the need for immunosuppressive drugs. Precise control over mesh size and 
mesh size uniformity is critical to prevent entry of cytokines or exit of islet antigens that can 
exacerbate the host immune response [131]. However, smaller mesh sizes that are close to the 
hydrodynamic radius of insulin can hinder molecular transport through the hydrogel. 
Furthermore, many cytokines are similarly sized to insulin, making it challenging to identify an 
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ideal mesh size that selectively excludes harmful proteins and small molecules [132]. The mesh 
size of the hydrogels presented here is approximately 10 nm [41], similar to other reported mesh 
sizes for PEG hydrogels [133, 134]. Encapsulating hydrogels were unable to delay graft allogeneic 
rejection and were not different from microporous hydrogels which offer no inherent protection 
from the immune system. Rejection occurred within a two-week timeframe post-transplant, 
similar to the microporous PLGA hydrogel, thus indicating that a semipermeable PEG membrane 
was not sufficient to delay graft rejection. However, in this study, a physical barrier to immune 
cells was not sufficient to prevent graft rejection. Precise control over mesh size and mesh size 
uniformity is critical to prevent entry of cytokines or exit of islet antigen that can exacerbate the 
host immune response.  
TGF-β1 release from PEG scaffolds delayed rejection of allogeneic islets. In vitro release 
of TGF-β1 from microporous hydrogels containing a protein loaded PLGA disc was similar to 
previously published porous PLGA systems in which 95% of the total delivered protein was 
detected by day 7 [117]. When encapsulating PEG scaffolds were implanted in the fat pad along 
with the TGF-β1 loaded disc, rejection was delayed until day 24 compared to rejection at day 12 
without TGF-β1. This demonstrates the ability to locally deliver proteins from the hydrogels and 
allows for the delivery of other anti-inflammatory molecules like IL-2, IL-10, or TNF-α inhibitors 









CHAPTER 4. Localized Lentivirus Delivery via Affinity Peptides 
 
4.1 Introduction 
 Biomaterial scaffolds serve a central role in regenerative medicine by creating a space for 
tissue growth and a support for cell interactions serve as a vehicle for gene delivery vectors as a 
means to localize expression of tissue inductive factors. The delivery of soluble factors to the 
local environment of the transplanted islets can promote survival, vascularization, and growth 
[135-137]. Localized expression of tissue inductive factors enables some control over the local 
microenvironment that has been effective in multiple models such as spinal cord injury and bone 
regeneration [73, 138] . The delivery of viral vectors from scaffolds has been attempted through 
a variety of approaches, such as non-specific adsorption of the vector [86], modifying the vector 
to bind to a material [90], or modifying the material to interact with the vector. Material 
modifications have included modification of surfaces with hydroxyapatite [87, 88], or 
phosphatidylserine that is known to have specific interactions with the vector [89]. Proteins and 
peptides are regularly employed to functionalize biomaterials, and are emerging as a tool for 
providing binding sites for vectors on material surfaces. Poly-L-lysine (PLL) with a molecular 
weight of 70-150 kDa has been used for delivery of viral vectors [63]. Identifying the design 
requirements for peptides or proteins for promoting efficient gene delivery would be invaluable 
for developing biomaterials for use in regenerative medicine.  
We investigated the design parameters for peptides and proteins to enhance delivery of 
lentiviral vectors from biomaterial scaffolds. Poly(ethylene glycol) based hydrogels were 
42 
 
employed as the biomaterial scaffold in these studies as they are widely used in vitro and in vivo 
for studies with cell culture, encapsulation, and transplantation and ultimately tissue formation, 
and provide a relatively low amount of non-specific binding for lentiviral vectors [107, 108]. 4-
arm PEG-acrylate hydrogels were functionalized with peptides containing a cysteine to provide 
quick and straightforward functionalization via Michael-type addition. The design of proteins and 
peptides for gene delivery initially employed PLL at a range of molecular weights. These studies 
investigated the mechanism by which PLL enhances gene delivery through characterizing virus 
binding and stability. While PLL can produce efficient delivery, the relatively high molecular 
weight and polydispersity of PLL may be a challenge for translation. We thus sought to identify 
peptides using a phage display technology, which has had success with identifying ligands for 
multiple cell types [139-143], proteins [144-146], and small molecules [147-149]. The peptides 
can provide a high affinity and specific binding interactions with the viral vector, and we 
investigated multiple strategies for their presentation from the hydrogel. Modifying biomaterials 
with peptides offers great potential to enhance and modulate virus localization and promote 
transgene expression for numerous regenerative medicine applications.  
4.2 Materials and methods 
4.2.1 Virus production  
Lentivirus was produced by co-transfecting HEK-293T cells with lentiviral packaging 
vectors (pMDL-GagPol, pRSV-Rev, pIVS-VSV-G), as previously described [150], and the gene of 
interest (pLenti-CMV-GFP and pLenti-CMV-GLuc) using jetPRIME (Polyplus Transfection, Illkirch, 
France). After 17 h, supernatant was replaced with fresh media containing 4 mM caffeine. After 
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an additional 31 hours, supernatant was collected and cell debris was spun down and removed. 
Virus particles were concentrated using PEG-it (Systems Biosciences, Mountain View, CA) and re-
suspended in PBS. Lentivirus titers were determined by qRT-PCR lentivirus titration kit (ABM, Inc., 
Richmond, Canada). Virus was further purified for SDS-PAGE gel analysis via a Lenti-X Maxi 
Purification Kit (Clonetech, Mountain View, CA) and desalted using a PD-10 column (GE 
Healthcare, Buckinghamshire, England). The SDS-PAGE gel used a NuPAGE 4-12% Bis-Tris pre-cast 
polyacrylamide gel and ran in MES SDS running buffer (Thermo Scientific) and stained with 
Coomassie Blue. 
4.2.2 PLL functionalization with cysteine 
 A low molecular weight PLL (10 kDa, Alamanda Polymers, Huntsville, AL) and a high 
molecular weight PLL (30-70 kDa, Sigma Aldrich, St. Louis, MO) were functionalized with a 
cysteine using EDC/NHS chemistry to facilitate incorporation into the PEG-acrylate hydrogels. A 
solution of 2 mM EDC and 5 mM NHS was added to a 0.1 M MES buffer (pH 5.0) and the peptide 
was added to make a concentration of 1 mg/mL. After 15 minutes of incubation, the buffer was 
exchanged with centrifugal filtration (10 kDa, Amicon Ultra-0.5) to 0.1 M PBS (pH 8) containing 
30 mg/mL of oxidized cysteine. After allowing the solution to react for 2 hours, excess cysteine 
was removed via dialysis and any oxidized thiol groups were reduced with 50 mg/mL of 
dithiothreitol. The PLL was quantified with a fluorescamine assay and the cysteines were 
quantified via Ellman’s test. 
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4.2.3 Macrophage differentiation  
Bone marrow derived macrophages (BMDM) were harvested and differentiated 
according to established protocol [151]. Briefly, femurs from male 8-12 week-old C57BL/6 mice 
(Charles River) were flushed to isolate bone marrow. Macrophages were cultured in RPMI 1640 
(Life Technologies, Carlsbad, CA) supplemented with 10% FBS (Life Technologies), 1% 
penicillin/streptomycin (Life Technologies), and 20% L929 conditioned media in untreated cell 
culture plates. Media was replaced on days 3, 6, and 8. On day 10, cells were removed using 0.05 
mM EDTA treatment. PEG hydrogels were formed and loaded with virus as described in materials 
and methods. Briefly, hydrogels were loaded with 107 viral particles encoding for GFP, washed to 
remove non-binding virus, then seeded with 104 macrophages per well in a 96-well plate. GFP 
expression was measured 72 hours later. 
4.2.4 Peptide synthesis 
Peptides were synthesized at Northwestern University’s Peptide Synthesis Core Facility of 
the Institute for BioNanotechnology in Medicine. To facilitate peptide incorporation into the PEG-
acrylate hydrogels via Michael-type addition, a cysteine was added to the C-terminus of the 
synthesized phage display peptide. 
4.2.5 Biotinylated VSV-G 
The VSV glycoprotein ectodomain (kindly gifted by Yves Gaudin, CNRS, Unité Mixte de 
Recherche) was biotinylated using sulfo-NHS-LC-biotin (Thermo Scientific, Rockford, IL) according 
to the manufacturer’s recommended methods. Briefly, VSV-G was diluted in a 0.1 M NaHCO3 
buffer and the biotinylation reagent was added. The reaction was incubated on ice for two hours 
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then excess reagent was removed using centrifugal filtration (10 kDa, Amicon Ultra-0.5). The 
degree of biotinylation on the VSV-G proteins was assayed using a fluorescence biotin 
quantitation kit (Thermo Scientific). 
4.2.6 Solution phase phage display 
 Peptides that bind to the biotinylated VSV-G protein were identified using a 12-mer phage 
display library (New England Biolabs, Ipswich, MA) using the suggested methods for solution 
phase panning. The phage library and biotinylated protein were combined in a TBS buffer with 
Tween-20 and allowed to interact. The mixture was then added to a streptavidin-coated 96-well 
plate blocked with BSA and incubated for 10 minutes. Biotin (0.5 µL, 10 mM) was added to 
displace any phages bound to the streptavidin and the plates were washed 15 times with TBST 
to remove non-binding phages. Bound phages were eluted from the immobilized protein by 
incubating in an acidic glycine elution buffer (pH 2.2) for 30 minutes followed by neutralization 
with 1 M tris buffer (pH 9.1). Phages were then amplified in E.coli and purified using a PEG 
solution (20% w/v). 
 A total of three rounds of panning were completed, with each round introducing more 
rigorous conditions to select for stronger binding candidates. Tween-20 concentration was 
increased 0.1, 0.5, and 1%, and NaCl concentration was increased 150, 300, and 750 mM. Time 
the phages spent incubating with the target protein was reduced to 60, 45, and 30 minutes. After 
the third round of panning, individual phage clones were randomly sampled and their DNA was 





 VSV-G was incubated in 96-well plates overnight and phage solutions were allowed to 
bind at the listed concentrations. After 30 minutes of incubation, phages were washed with a 
buffered solution containing 1% Tween-20 and 750 mM NaCl. Phages were detected with an anti-
M13 bacteriophage antibody conjugated with horseradish peroxidase (HRP) (GE Healthcare) and 
reacted with a 1-step 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt 
(ABTS) to produce a colorimetric reaction. The absorbance from the reaction was measured using 
a plate reader (Synergy 2, BioTek). 
4.2.8 Hydrogel preparation 
Hydrogels were formed by dissolving 4-arm polyethylene glycol acrylate (20 kDa) (Laysan 
Bio, Inc., Arab, AL) in 8.5 mM HEPES buffer (pH 8.0) at a concentration of 100 mg/mL. In hydrogels 
containing PLL, cysteine-functionalized PLL was added for a total concentration of 0.45 mg/mL, 
unless otherwise noted, in addition to 2.5 mM of the cell adhesion peptide, RGD (Ac-CGRGDS-
NH3) (Celtek Peptides). The RGD control gels contained 5 mM of the peptide. The PEG precursor 
solution was incubated at 37 ˚C for 30 minutes to facilitate the Michael-type addition between 
the acrylate and thiol. To initiate the free-radical polymerization of the acrylate groups, Irgacure 
2959 dissolved in N-vinylpyrrolidinone (600 mg/mL) was added to the PEG for a final 
concentration of 1% (wt/vol). Gel precursor was added to non-adhesive silicon molds (diameter 
= 4.5 mm, height = 0.8 mm), cross linked with UV light for 90 seconds, then washed with PBS to 
remove unbound peptide and unreacted photoinitiator. To determine if virus binding to the walls 
of the polystyrene plate affected the results, wells of a tissue culture treated 96-well plate were 
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blocked with bovine serum albumin (5 mg/mL in 0.1 M NaHCO3 buffer, pH = 8.6). No significant 
binding was observed.  
Hydrogels functionalized with peptides from the phage display panning used a 5 kDa PEG 
linker (acrylate – PEG – maleimide) (Creative PEG Works, Winston Salem, NC). The PEG linker was 
added to the PEG precursor solution at a 2.5 mM concentration then photopolymerized using UV 
light. The peptides were incubated with the virus for 3 hours and then incubated with the 
hydrogels for 15 minutes, with hydrogels subsequently washed 2x with PBS. 
4.2.9 Transgene expression 
 Lentivirus (1 x 107 particles) was added to the gels and allowed to incubate for 3 hours at 
room temperature (unless otherwise noted). Virus solution was then removed and gels were 
washed twice with 150 μL of PBS to remove unbound virus. HT1080 cells were added (104 cells / 
well) and incubated with Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum at 
37oC, and 5% CO2. Cells expressing GFP were imaged 72 hours later, unless noted otherwise, 
using Leica X fluorescent microscope. The supernatant of cells expressing GLuc was gathered 
after 72 hours of incubation and measured using a Gaussia luciferase assay kit (New England 
BioLabs) with a luminometer (Turner Design, Sunnyvale, CA).  
4.2.10 Statistics  
 One-way ANOVA followed by Tukey’s posttest for multiple comparisons and two-tailed 
Student’s t-test, where appropriate, was performed using GraphPad version 5.04 for Windows 
(La Jolla, CA). Statistical significance was set at p ≤ 0.05 unless noted. Values shown represent the 




4.3.1 PLL length 
PEG hydrogels were functionalized with PLL of three molecular weights and subsequently 
investigated for their ability to localize lentiviral vectors to the substrate and promote gene 
transfer. PLL was modified with cysteine for attachment to the acrylate groups on the PEG 
hydrogel. Studies were performed with varying molecular weights of PLL, which were 
incorporated at equal masses (Table 4-1). Hydrogels functionalized with 1 kDa, 10 kDa, or 30-70 
kDa PLL were incubated for three hours with lentivirus encoding for GFP. Fluorescence images 
demonstrated that the high molecular weight PLL (30-70 kDa) provided the greatest number of 
GFP positive cells (Fig. 4-1C), while the 1 kDa PLL had almost no cells expressing the transgene 
(Fig. 4-1A). The high molecular weight PLL resulted in transduction of 25% of the cells, whereas 
the lowest molecular weight PLL transduced less than 0.1% of the cells (Fig. 4-1D). Based on its 
ability to promote the greatest extent of transduction relative to the other PLL’s, the 30-70 kDa 
was selected for further analysis. To demonstrate this system’s broad potential to transduce 
other cell types, bone marrow derived macrophages were isolated from mice and incubated with 
hydrogels functionalized with 30-70 kDa PLL (Fig. 4-2).  The extent of transgene expression for 
the virus immobilized to the hydrogel was subsequently characterized. The control condition for 
this study involved hydrogels without PLL, yet had the cell-adhesion peptide RGD, which is 
necessary for cell adhesion and provides minimal interactions with the virus. The assay displays 
effectively zero background signal in the absence of virus, indicating that any measured signal is 
produced via transgene expression (Fig. 4-3). Additionally, designated wells were blocked with 





Table 4-1. Equal masses of the different poly-L-lysines were added to provide an identical net 




Figure 4-1. Influence of PLL molecular weight on virus localization. PEG hydrogels containing 2.5 
mM RGD were functionalized with 0.45 mg/mL of 1 kDa (n=3) (A), 10 kDa (n=3) (B), and 30-70 
kDa (n=5). (C) PLL and incubated with GFP-encoding lentivirus. Hydrogels were washed to remove 
non-binding virus then seeded with HT1080 cells for 72 hours. (D) Significantly more cells were 




Figure 4-2. PLL functionalized hydrogels promote transduction of macrophages. PEG hydrogels 
were functionalized with 2.5 mM RGD (A) and 2.5 mM RGD + 1.35 mg/mL of 30-70 kDa PLL (B). 
Conditions without PLL (A) had no GFP expression while PLL functionalized hydrogels 






addition in order to determine the contribution of virus binding to the plastic walls of the plate. 
No significant difference was detected between blocked and unblocked plates. Luciferase activity 
was more than 10-fold greater on the PLL-containing gels relative to the control hydrogels, and 
the control gels were not statistically different from gels without virus.  
4.3.2 Binding dynamics, release, and stability 
We subsequently investigated the duration over which virus was incubated with 
hydrogels and the density of functionalization, as both have been previously reported to 
influence the binding of non-viral vectors and the extent of transgene expression. Hydrogels were 
functionalized with PLL and incubated with virus for times ranging from 15 to 270 minutes. A 
significant increase in luciferase activity was observed for virus incubated for 90 minutes with the 
hydrogels, with longer incubations of 270 minutes having no significant effect on transgene 
expression (Fig. 4-4A). The PLL concentration similarly influenced transgene expression, with 
increasing transgene expression observed between 0.15 and 1.35 mg/mL, and subsequent 
increases to 4.05 mg/mL not significantly affecting transgene expression (Fig. 4-4B). These 
observed trends in incubation time and PLL concentration are consistent with those reported for 
non-viral vectors, and are likely due to the quantities of the lentivirus associated with the 
substrate.  
The release of lentivirus from PLL-functionalized PEG gels was investigated, as retention 
of the vector at the material can localize gene delivery. After virus incubation with the hydrogel 
and subsequent washing, released virus in the supernatant was collected and quantified with RT-
qPCR (Fig. 4-5A,B). After washing, the PLL modified hydrogel did not have detectable levels of 




Figure 4-3. PLL enhances virus localization on PEG hydrogels. PEG hydrogels containing 2.5 mM 
RGD were functionalized with either 30-70 kDa PLL (0.45 mg/mL) or additional RGD (2.5 mM) 
(n=3). Designated wells were blocked with BSA (5 mg/mL) prior to forming the hydrogels. The 
“No virus” condition contains PLL but was incubated with PBS instead of lentivirus. Lentivirus 
encoding for GLuc was incubated with the hydrogels then washed with PBS to remove non-
binding virus. HT1080 cells were incubated with the hydrogels for three days and then luciferase 




Figure 4-4. Transgene expression can be modulated via virus-hydrogel incubation time and PLL 
concentration. (A) PEG hydrogels functionalized with 2.5 mM RGD and 0.45 mg/mL of PLL were 
incubated with virus for varying times (n=3). Fold increase in GLuc expression relative to RGD 
control. Significant difference compared to RGD control (**p≤0.01; ***p ≤0.001). (B) Hydrogels 
were functionalized with varied concentrations of PLL and incubated with virus for 3 hours (n=3). 
Significant difference compared to RGD control (****p≤0.0001).  
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the duration of the study (Fig. 4-5B). In a separate experiment, trypsin was added to PLL-
conjugated hydrogels loaded with virus to elute bound lentivirus, but no detectable amounts of 
eluted virus could be detected. It is hypothesized that the trypsin may have damaged the 
lentivirus or inhibited the RT-qPCR reagents. The stability of the immobilized virus, another factor 
affecting transduction, was subsequently investigated by incubating hydrogels with immobilized 
virus at 37 oC for varying amounts of time. Following incubation, cells were seeded onto the 
hydrogels and luciferase expression was assayed at 72 hours. Increasing times of incubation led 
to decreased levels of transgene expression for both the PLL condition and the RGD control, and 
this decline in activity was used to determine a half-life of activity. The half-life of lentivirus on 
the control hydrogel was 8.3 hours, consistent with previous reports [152-154], whereas the PLL-
functionalized hydrogels demonstrated a half-life of 10. hours, a 20% increase in half-life relative 
to control (p≤0.05) (Fig. 4-6).  
4.3.3 VSV-G protein solution-phase panning 
We subsequently sought to replace the high molecular weight PLL with a peptide, which 
are routinely used to functionalize biomaterials. The low molecular weight PLL has an insufficient 
affinity for lentivirus binding, and subsequently applied phage display to identify peptides with a 
high affinity for the lentivirus. Phage display requires a highly pure target to prevent undesired 
sequence selection, so two lentivirus purification techniques were explored and their purity was 
tested with an SDS-PAGE protein gel (Fig. 4-7). The PEG precipitation technique (lanes 7,8) 
resulted in a relatively large quantity of protein coprecipitated with the virus. The affinity column 
(lanes 5, 6) removed the majority of protein detected in the PEG precipitation, but a faint band 







Figure 4-5. Retention of lentivirus on PLL-functionalized PEG hydrogels. (A) PEG hydrogels 
containing 2.5 mM RGD were functionalized with either 30-70 kDa PLL or additional RGD (0.45 
mg/mL) (n=4). Virus was incubated with the hydrogels for three hours at 37 oC then washed with 
PBS to remove non-binding virus. Unbound virus in the supernatant was collected and assayed 
via qPCR at different time points. Following the two washes, no detectable level of virus was 
found in the PLL-functionalized hydrogels. (B) The fraction of lentivirus released from the 
hydrogel was calculated by dividing the eluted virus particles by the initial virus loading. 
Significant differences between corresponding RGD and PLL conditions are denoted by an 









Figure 4-6. Increased viral stability in PLL-functionalized hydrogels at 37oC. PEG hydrogels with 
2.5 mM RGD and either 30-70 kDa PLL or additional RGD (0.45 mg/mL) were incubated with virus 
at 37 oC for three hours (n=3). All hydrogels were washed and incubated with PBS. At each time 
point, the PBS was replaced with HT1080 cells and subsequent luciferase expression was assayed 




Figure 4-7. Analysis of lentivirus purification methods using SDS-PAGE protein gel. (Lane 1, 3 = 
VSV-G, 0.5 µg; lane 4, 5 = VSV-G, 2.0 µg; lane 6, 7 = Lentivirus, Lenti-X purification; lane 8, 9 = 
Lentivirus, PEG-it purification; lane 10 = ladder; Lane 2 intentionally left blank). The Lenti-X 
affinity column removed almost all detectable amounts of contaminating protein, except for a 
faintly detectable band at approximated 65 kDa whereas the PEG-it precipitation failed to 




in the presence of contaminating proteins at sufficient quantities that prohibited solution-phase 
phage display. 
Phage display was thus applied to the envelope protein of the lentivirus, VSV-G (Fig. 4-8). 
VSV-G was biotinylated at a ratio of 0.8 mol of biotin per 1 mol of VSV-G protein. The protein was 
biotinylated at slightly less than a 1:1 ratio of biotin to protein in order to minimize the risk of 
phage display targeting excessive biotin groups on the protein. Initial panning experiments 
utilized a 7-mer sequence and resulted in strong selection of double insert phages. Phage display 
libraries contain a small percentage of phages containing multiple inserts of the randomized 
peptide sequence and these clones are strongly selected for when the ligand specificity spans a 
distance greater than the seven amino acid sequence. Consequently, panning experiments 
utilized phages with a longer 12-mer randomized sequence.  
Three rounds of panning with the VSV-G protein were performed to enrich the phage pool 
for VSV-G binding sequences. The binding specificity of these sequences was assessed using a 
fourth round of panning with and without the VSV-G protein, with 105 pfu/µL phages bound in 
the presence of the VSV-G protein, and 101 pfu/µL in the absence of the protein (Fig. 4-9), 
confirming the eluted phages are enriched in VSV-G specific phage clones. From solutions with 
the target protein, 108 phage clones were sequenced.  The relative variance of these sequences 
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Figure 4-8. Solution phase phage display. Biotinylated VSV-G and the phage library are mixed (1) 
and allowed to incubate (2). (3) Phage/VSV-G complexes are captured on a streptavidin-coated 
plate and non-binding phages are washed away (4). VSV-G bound phages are eluted from the 
plate using a low pH buffer (5) and the phages are collected for additional rounds of panning. 
 
 
Figure 4-9. After three rounds of panning, phages demonstrate binding affinity to VSV-G. A fourth 
round of panning was completed with (+) and without (-) VSV-G immobilized on the plate surface. 
After washing to remove non-binding phages, 105 PFU/µL were eluted from the plate surface 





Where Nmax is the number of times the highest occurring amino acid appeared at a given position, 
NTotal is the total number of peptides sequences considered, and Nseq is the number of unique 
amino acids at a given position. The peptide sequence is listed N to C terminus, where the peptide 
is attached on the N-terminus of the phage’s pIII coat protein. Thus, amino acids at position 1 are 
farthest from the phage body and position 12 are closest. In between the randomized 12-mer 
sequence and the phage body is a GGGS spacer that is not included in the relative variance 
analysis. The results shows a high degree of relative variability at amino acids proximal to the 
phage (positions 9, 10, 11, 12) and an area of low variability in the center (positions 4, 5, 6, 7) and 
distal from the phage (position 1) (Fig. 4-10). This area of low variability in the center corresponds 
to a high frequency of the amino acid histidine. Next, the sequence STQHHHHSKQSR (STQ) was 
selected for binding analysis in an ELISA. Wells were coated with VSV-G and phages from either 
the naïve 12-mer library or phages displaying the STQ sequence were incubated with the target 
protein. After washing, bound phages were quantified with an anti-M13 bacteriophage antibody 
conjugated with HRP and reacted ABTS. Due to the high concentration of VSV-G bound on the 
plate which allows for multivalent binding to the phage, this technique cannot produce a 
dissociation constant (KD). However, it provides information on the relative binding affinities and 
can distinguish target binding from background binding to the plastic plate. ELISA results 
confirmed affinity binding for the STQ sequence compared to the non-specific binding of the 
naïve phage library (Fig. 4-11).  
After confirming with ELISA that the STQ sequence demonstrated an affinity for VSV-G, it 
was synthesized along with three other peptides that appeared multiple times for further analysis 





Figure 4-10. Relative variability analysis of the sequences derived from phage display shows a 
decreased variability at position 1 and 4-7. Position 12 is closest to the phage body and position 
1 has the most freedom of movement. This analysis removed any repeat sequences.  
 
 
Figure 4-11. ELISA results of the STQ phage shows increased binding compared to the naïve phage 
library. As the titer of phages added to VSV-G coated plates was increased, phages displaying the 
STQ sequence demonstrated increased binding whereas the non-specific naïve library did not 




subsequently investigated. Peptides were synthesized with a terminal thiol group, and initial 
studies incorporated these peptides through Michael type addition, consistent with the 
mechanism of attachment for PLL and RGD peptides. The peptide density and incubation time of 
the peptide with virus were those identified to maximize expression with PLL (Fig. 4-4). Peptides 
that were directly incorporated into the PEG hydrogel failed to promote transgene expression. 
Subsequent studies involved attaching a 5 kDa PEG linker to the peptide, which was hypothesized 
to provide greater flexibility for lentivirus binding. PEG hydrogels functionalized with linker-
modified peptides promoted substantial transgene expression (Fig. 4-12). The four peptides 
identified by phage display provided a 6- to 20-fold increase in luciferase activity relative to RGD 
modified hydrogels (with RGD presented on a linker), and had expression levels that were 
comparable to the 30-70 kDa PLL. The use of the linker to connect the peptide to the hydrogel 
enhanced expression by the 30-70 kDa PLL relative to the absence of the linker (Fig. 4-2). 
Interestingly, a 1 kDa PLL peptide immobilized on a linker did not promote significant gene 
transfer above that produced with RGD. Taken together, these results indicate that peptides can 
promote substantial transgene expression by immobilization to hydrogels, though their 
presentation on a linker is necessary.  
4.4 Discussion  
This chapter investigated the design of peptides for immobilization of lentivirus to 
hydrogels and subsequently promote transgene expression. PLL is a cationic polypeptide that has 
been previously employed in non-viral gene delivery and has also been used to modify 









Figure 4-12. Phage display identified peptides specific to the VSV-G protein on the lentivirus. 
Specific binding of lentivirus to phage display peptides. PEG hydrogels were functionalized with 
2.5 mM RGD and 2.5 mM of the synthesized phage display peptides conjugated with a 5 kDa PEG 
linker (n=4). HLKHTHNTHYKTCG (“HLK”), HWKPHSNLHLSRCG (“HWK”), STQHHHHSKQSRCG 
(“STQ”), and WPGHHNHSMKHKCG (“WPG”). RGD and 30-70 kDa PLL (0.45 mg/mL) were also 
functionalized to the PEG linker to serve as negative and positive controls, respectively. Lentivirus 
was incubated with the hydrogels for 3 hours followed by washing to remove non-binding virus. 
HT1080 cells were seeded on the hydrogels and luciferase activity was assayed 72 hours later. 
Fold increase in GLuc expression relative to RGD control. Significant differences between RGD 






vector through non-specific interactions. Our studies, consistent with previous reports [155], 
demonstrated that relatively high molecular weight PLL led to greater transgene expression. The 
enhanced transgene expression likely results from the retention of virus at the surface, which 
would overcome mass transport limitations by localizing the virus to the substrate to which cells 
were adhered [156, 157]. Immobilization also served to increase the stability by approximately 
20%, and the extent of immobilization increased through concentrations of 1.35 mg/mL and 
subsequently reached a plateau. Hydrogels functionalized with PLL concentrations higher than 
4.05 mg/mL were generally associated with decreased cell viability. Gene expression could 
theoretically be further manipulated by modifying PEG concentration, the molecular weight of 
PEG, and the amount of loaded virus. The collection of positive charges presented by the PLL 
provide sufficient avidity to effectively act to bind, yet the interaction between the virion and cell 
is sufficient to disrupt the PLL-lentivirus binding. 
PEG hydrogels were functionalized with PLL at multiple molecular weights (1 kDa, 10 kDa, 
and 30-70 kDa). These studies were performed for a similar extent of surface modification to 
isolate the effect of chain length. These studies demonstrated a significant effect of the chain 
length, with the shortest not supporting binding, the intermediate providing low level 
transduction, and the longest providing the greatest levels of expression. The peptide RGD served 
as a control for these studies and small quantities of virus was associated with this condition; 
however, this low association may be influenced by non-specific interaction with the hydrogel.  
We sought to identify shorter peptides for virus immobilization, as large peptides can be 
difficult to work with, relatively expensive, and have potential for cytotoxicity. The results with 1 
kDa PLL indicated that the peptide would need greater affinity, and thus phage display was used. 
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Phage display requires a highly pure target, which was not achievable with the existing lentivirus 
purification kits (LentiX). The crystal structure for the pre-fusion form of the VSV-G protein had 
recently been determined [158], and the purified VSV-G ectodomain was generously provided by 
the Gaudin group. Using the 12-mer library, we identified 108 clones, and the sequences that 
were most commonly observed were investigated for lentivirus binding. The STQ sequence was 
obtained with the greatest frequency after sequencing the phage clones. Several of the non-STQ 
sequences displayed a preference for four histidines at amino acid positions 4, 5, 6, and 7. A high 
abundance of aromatic amino acids could signify that the phages are interacting with the plastic 
instead of the target protein [159, 160]. In a fourth round of panning, the phages showed a 
10,000-fold higher binding affinity for wells coated with VSV-G, suggesting that our experiments 
did not identify proteins based on non-specific binding to the plastic. The precise nature of how 
this histidine motif interacts with VSV-G will need to be explored in future studies.  
Peptides identified through phage display were able to support transduction if a linker 
was employed for peptide immobilization. Initial studies with direct peptide attachment to the 
PEG hydrogel had minimal levels of transgene expression. Linkers have been used by others to 
conjugate antibodies to epidermal growth factor (EGF) , which were hypothesized to reduce 
steric hindrance and thereby improve interactions between the target [161]. Peptide 
immobilization with a 5 kDa PEG linker led to significant transgene expression, with the STQ and 
WPG peptides providing the greatest levels of expression. Interestingly, the transgene expression 
levels obtained with the immobilized peptide were comparable to the levels obtained with the 
relatively high molecular weight PLL. A linker applied to the 30-70 kDa PLL increased transgene 
expression by approximately 80%, yet was required for the peptides. Finally, we note that the 
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affinity provided by the peptides identified by phage display was necessary for transduction, as 
a 1 kDa PLL did not support gene transfer.  
Viral gene delivery represents a versatile tool to modify the microenvironment of 
damaged or diseased tissue and promote regeneration by converting the transduced cells into 
bioreactors to produce therapeutic proteins or downregulate undesired genes. Hydrogels are 
employed as a substrate that creates a space to promote regeneration, possess mechanical 
properties similar to native extracellular matrices, and can be readily functionalized. Hydrogels 
functionalized with proteins or peptides capable of binding lentivirus retained the virus at the 
material, enhanced the virus stability, and ultimately promoted gene transfer. High molecular 
weight proteins that non-specifically bind the lentivirus were directly attached to support binding 
and gene transfer. Alternatively, short peptides that specifically bind the lentivirus had to be 
immobilized onto biomaterials through linkers in order to promote binding and gene transfer, 
yet offered comparable gene expression levels. Taken together, affinity peptides or proteins can 
be attached to biomaterials to promote the binding of gene therapy vectors and subsequent gene 










Graft rejection is a central limitation in current clinical islet transplants. Although 
improvements in immunosuppressants have improved graft survival, chronic administration of 
these drugs leads to additional complications [18, 162]. In contrast, localized modulation of the 
immune system provides tolerance in allogeneic hosts without body-wide negative side effects 
associated with systemic immunosuppressants. Encapsulating hydrogels are a widely explored 
alternative that create a semipermeable membrane designed to block immune cells and exclude 
inflammatory cytokines while allowing insulin, nutrients, and waste to diffuse across the barrier 
[163-166]. Consequently, this approach excludes blood vessel infiltration and, in the absence of 
adequate blood supply, islets face acute hypoxic stress and poor insulin exchange [167]. As 
demonstrated in Chapter 3, microporous scaffolds are an attractive option due to their rapid 
engraftment and response to changes in blood glucose levels, but they do not offer any inherent 
protection from the immune system. Therefore, the purpose of this chapter is to demonstrate 
the feasibility of functionalizing microporous scaffolds with immunoregulatory proteins to locally 
induce islet tolerance.  
Destruction of β cells in T1D is caused by autoreactive T cells responding to β cell-specific 
antigens [91]. Experimental evidence suggest that the direct recognition of class I MHC molecules 
on the surface of islet cells by CD8+ T cells plays a critical role in islet allograft rejection [168-171].  
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Controlling the auto- and allogeneic T cell response would allow for long term survival of 
transplanted islets. Fas ligand (FasL), a well-studied regulatory protein, binds to cells expressing 
the FasR and plays an important role in tolerance to self-antigens [172-175]. Previous attempts 
to utilize the regulatory capability of FasL were met with some success by transplanting a 
composite graft consisting of islets and syngeneic myoblasts transfected to express FasL [176], 
but it was later demonstrated that this approach was prone to neutrophil-mediated 
inflammation [177]. Similarly, other groups have utilized islets that directly expressed FasL, but 
also encountered rapid islet death from host neutrophils [178, 179]. As an alternative to ectopic 
gene expression, islets were biotinylated and functionalized with a streptavidin-FasL (SA-FasL) 
chimera protein that has shown indefinite cell survival when combined with a short course of 
rapamycin [180].  
It is clear that FasL is a potent immunoregulatory molecule and localized delivery of FasL 
represents an attractive option, but proper presentation of the protein remains a challenge. 
Although surface decoration of FasL on biotinylated islets has demonstrated robust tolerance, 
manipulating a biomaterial scaffold to present SA-FasL would eliminate the steps needed for 
direct islet engineering, and as such save time and overcome potential undesired effects 
associated with engineering process, such as cell fragmentation. The studies in this chapter 
describe the attachment of SA-FasL to microporous scaffolds to achieve chronic 
immunosuppression-free, long-term survival of allogeneic pancreatic islets transplanted into an 
extrahepatic site. Initial studies employed the established model in which islets are modified with 
SA-FasL, with subsequent transplantation onto a microporous scaffold. Subsequently, we 
developed the procedures for modifying microporous PLGA scaffolds with biotin for subsequent 
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immobilization of SA-FasL, and characterized the binding and functionality of the immobilized 
protein. Although it would be desirable to utilize PEG hydrogels due to their tissue-like 
mechanical properties and ease of functionalization, PLGA scaffolds were used in these studies 
as allogeneic transplants in this material is already well-characterized. These studies employed 
islets isolated from BALB/c mouse and transplanted into the epididymal fat pad of C57/BL6 
mouse, a fully mismatched transplantation model. The omentum has emerged as a leading 
candidate in human clinical trials due to its thin and highly vascularized membrane, and portal 
draining that recreates the physiological effects of insulin in the liver [34, 181]. In mice, the 
epididymal fat pad has many similar features to the omentum, and we have developed scaffolds 
to support engraftment of transplanted islets at this site. The function of the transplanted islets 
was monitored by blood glucose levels as well as an intraperitoneal glucose tolerance test. 
Collectively, these studies address two major issues with clinical islet transplantation; 
development of an extrahepatic site for islet engraftment, and overcoming immune rejection 
without of the use of chronic immunosuppression.  
5.2 Materials and methods 
5.2.1 Materials:  
Poly(lactide-co-glycolide) (75:25) (PLGA) (approx. 80,000 g/mol) with a single carboxylic 
acid end-group and an inherent viscosity of 0.76 dL/g was purchased from Lakeshore 
Biomaterials (Birmingham, AL). Poly(ethylene-alt-maleic anhydride) (PEMA) was purchased from 
Polyscience, Inc. (Warrington, PA). EZ link Amine-PEG2-Biotin was purchased from Fisher 
Scientific. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-
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hydroxysuccinimide (NHS). Dichloromethane (DCM), dimethyl sulfoxide (DMSO). All other 
reagents were purchased from Sigma Aldrich (St. Louis, MO) unless noted otherwise.  
5.2.1 Biotinylation of PLGA and characterization  
PLGA (890 mg, 0.011 mmol) was added to a 20 mL glass scintillation vial and dissolved in 
10 mL DMSO.  The carboxyl end group of PLGA was activated by first adding EDC (10.6 mg, 0.056 
mmol) dissolved in 1 mL DMSO followed by NHS (6.4 mg, 0.056 mmol) dissolved in 1 mL DMSO 
and the reaction was allowed to stir for 15 min. Amine-PEG2-Biotin (5 mg, 0.056 mmol) was 
dissolved in 1 mL DMSO and added dropwise to the stirring solution of PLGA-NHS and the 
reaction was allowed to stir overnight. Excess biotin was removed by extraction. The reaction 
mixture was diluted into 200 mL of DCM and washed 4 times with 150 mL of brine.  The organic 
layer was dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation, 
precipitated into ice cold methanol, and stored in vacuum overnight to remove residual solvents.  
Functionalization was confirmed with 1H-NMR (DMSO-d6). 
5.2.2 Particle and scaffold fabrication 
PLGA microparticles were formed for scaffold fabrication as previously described [182].  
Briefly, PLGA was dissolved in DCM at a concentration of 6 wt% and sonicated in a 1% solution of 
PEMA at 100% amplitude (Cole-Parmer, 130 W, 3 mm stepped tip). The emulsion was poured 
into 200 mL of 0.5% PEMA and the organic solvent were evaporated by stirring the emulsion 
overnight. The particles were recovered by washing four times with deionized water by 
centrifugation at 7000 x g for 15 min at 4 oC. Particles were lyophilized for 48 hours and stored 
under vacuum.  Biotin-PLGA microparticles were similarly fabricated, however biotin-PLGA 
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conjugates were combined with unmodified PLGA at a mass ratio of 3:1 (biotin-PLGA:PLGA) for a 
final concentration of 6 wt% in DCM.  
Porous scaffolds were formed by mixing PLGA particles with NaCl (250 µm< d < 425 µm) 
at a 1:30 ratio (PLGA:NaCl).  The mixture was pressed in a 5 mm KBr die using a Carver press at 
1500 psi and foamed in CO2 at 750 psi for 16 hours.  Scaffolds were leached in water for 1 hour 
followed by a second wash for 30 minutes.  Scaffolds were disinfected by soaking them in 70% 
ethanol and washed with deionized water. 
5.2.3 Particle characterization 
The size and zeta potential of the particles was determined by dynamic light scattering 
(DLS) by mixing 10 μL of a 25 mg/mL particle solution into 990 μL of MilliQ water using a Malvern 
Zetasizer ZSP (Westborough, MA) as previously described [Citation]. 
5.2.4 Scanning electron microscopy 
SEM images were taken using a scanning electron microscope (FEI Quanta 3D) 
instrument. A gold sputter coating was applied and the microscope was operated at 10 kV. 
5.2.5 Protein loading and quantification 
 Particles were incubated with various concentrations of fluorophore-labeled streptavidin 
at 1 mg particles/mL for 20 minutes at various concentrations.  Unbound streptavidin was 
removed by washing the particles with PBS by centrifugation (7000 x g, 5 min, 4 deg. C). To 
quantify the amount of fluorophore binding to the particles, particles were dissolved in DMSO 
and fluorescence was quantified using a plate reader,(Synergy 2 (BioTek)) at 578 nm excitation 
and 605 nm emission. 
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 Scaffolds were incubated with fluorescent streptavidin by applying 10 µL of the SA 
solution (0-40 ng/µL) to both sides of the disc (a total of 20 µL) for 20 minutes.  Unbound 
streptavidin was removed by washing the scaffold three times with 1.5 mL of PBS in a 
microcentrifuge tube.  Scaffolds were dissolved in DMSO and fluorescence was quantified as 
described above. 
5.2.6 Apoptosis assay 
 Particles (1 mg) and scaffolds were incubated with SA-FasL (supplied by the Shirwan lab, 
University of Louisville, KY) (Particles: 1 mL, 400 ng/µL; scaffold: 20 μL, 0-50 ng/μL) and washed 
as described above.  To assess the ability for FasL particles or scaffolds to induce apoptosis in 
vitro, 1 mg/mL particles or a single scaffold was added to a 96 well plate containing A20 cells 
(mouse B lymphoma) at a concentration of 1.5x106 cells/mL and incubated for 18 hours.  Cells 
were removed from the plate, stained with annexin V and propidium iodide (Life Technologies), 
and analyzed via flow cytometry. 
5.2.7 Mice and recombinant proteins 
Animal studies were completed at the University of Louisville in collaboration with the 
Haval Shirwan lab. C57BL/6 (H-2b) and BALB/c (H-2d) mice were purchased from Jackson 
Laboratory and bred according to protocol as approved by the Institutional Animal Care and Use 
Committee in our specific pathogen-free animal facility at the University of Louisville. 




5.2.8 Islet isolation and engineering with SA-FasL protein 
BALB/c islets were harvested from 8 to 12-week-old donors under anesthesia. Donor 
pancreases were perfused with 3 mL of cold Liberase TL (Roche Diagnostics) then removed and 
incubated for 20 minutes at 37oC.  Islets were isolated using a Ficoll gradient (Sigma-Aldrich). 
Islets were kept overnight in RPMI-1640 medium supplemented with penicillin/streptomycin 
(100 U/ml and 100 µg/ml) and 10% fetal bovine serum in an incubator at 37oC with 5% CO2.  Islets 
were transferred to a 14-mL round bottom tube and washed in PBS. Islets were then incubated 
in 5 µM EZ-Link™ Sulfo-NHS-LC-Biotin solution (Thermo Scientific) at 20oC for 30 minutes. After 
incubation, islets were washed twice in PBS to remove any unbound biotin. Then, islets were 
incubated in PBS containing SA-FasL protein (~200 ng SA-Fas/500-550 islets/200 µl PBS) at 20oC 
for 30 minutes. Islets were washed twice in PBS to remove any unbound protein before 
transplantation. Biotin-PLGA scaffolds were engineered by placing scaffolds to a round bottom 
tube and adding SA-FasL (0.5 or 2.5 µg /scaffold) diluted in PBS and incubating at 20oC for 30 
minutes while rotating and shaking the tube every 10 minutes. Scaffolds were washed twice 
before being loaded with islets. 
5.2.9 Islet transplantation 
C57BL/6 mice were chemically induced with diabetes by intraperitoneal (i.p.) injection of 
streptozotocin (200 mg/kg). Mice were monitored by reading blood glucose where ≥ 250 mg/dL 
for two consecutive days was considered diabetic.  Islets were loaded onto PLGA scaffolds (2 
scaffolds/mouse). Diabetic mice were given anesthesia and a small incision was made on the 
abdomen to allow scaffolds to be placed on epididymal fat pads. Adipose tissue was wrapped 
around scaffolds before being returned to the abdomen. Mice were then sutured. Select mice 
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were administered with rapamycin through i.p. injection of 0.2 mg/kg daily for 15 days starting 
the day of transplant. Mice were monitored for diabetes and those with ≥ 250 mg/dL blood 
glucose level for two consecutive days considered rejecting the islet graft. 
5.2.10 Intraperitoneal Glucose Tolerance Test 
Mice were put in clean cages without food and allowed to fast for 6 hours. After fasting, 
mice were injected with 25% glucose solution (2 gm/kg body weight). Mice were monitored for 
blood glucose levels before injection and at 10, 20, 30, 60, 90, and 120 minutes post glucose 
injection. 
5.2.11 Immune monitoring 
Spleen and draining lymph nodes were harvested from mice after rejection of graft or at 
experimental end point (> 200 days) if mice remained euglycemic up to that point. Organs were 
disassociated into single cell suspensions by shearing between two frosted slides. ACK lysis buffer 
(ThermoFisher Scientific) was added to spleen to lyse red blood cells. For T cell phenotyping, after 
washing and counting, cells were stained with antibodies for surface markers (Alexa 700-CD4 Ab, 
APC-Cy7-CD8 Ab, PE-Cy7-CD25 Ab from Pharmingen, BD, and eFlour 450-CD44 Ab and PerCP-
Cy5.5-CD62L Ab from eBioscience). Cells were then fixed and permeabilized, and FoxP3 staining 
was done using FoxP3 Transcription Factor Staining Buffer set (eBioscience).  
For mixed lymphocyte reaction, splenocytes were panned and labelled with CFSE. 
Stimulator cells were prepared from either naïve BALB/c (donor) or C3H (3rd party) mice, 
irradiated with 200 cGy, and cocultured with equal numbers of responder cells in 96-well plates 
(0.1x106 cells/well). Cells were cultured in 200 µL DMEM supplemented with HEPES buffer, 
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sodium pyruvate, penicillin/streptomycin, L-Glutamine (ThermoFisher Scientific), FBS, L-Arginine 
HCL, folic acid, L-Asparagine, 2-Mercaptoethanol (Sigma), and responder serum. Cells were 
harvested after four days of culture at 37°C and stained with Alexa 700-CD4 Ab, APC-Cy7-CD8 Ab, 
and 7AAD to separate dead cells (BD Pharmingen). Cells were analyzed using BD LSR II and 
analyzed using Diva software. 
5.2.12 Statistical analysis 
Flow data was tested for significance using a two tailed Welch’s t-test. Graft survival was 
tested for significance using the log-rank test. P values of <0.05 were considered significant. 
Survival curves, IPGTT, and flow graphs were created and analyzed using GraphPad Prism 
software. 
5.3 Results 
5.3.1 Transplantation of SA-FasL modified islets onto microporous scaffolds 
We investigated the transplantation of SA-FasL on microporous scaffolds implanted into 
the epididymal fat pad (Fig. 5-1A). Initial studies employed the transplantation of syngeneic islets 
into streptozotocin-induced diabetic mice to determine the impact of the scaffolds and short 
term rapamycin on the engraftment and function of the transplanted islets. Transplantation of 
the syngeneic islets led to the establishment of euglycemia within 10 days for all animals, and the 
animals maintained euglycemia for the duration of the study (200 days) (Fig. 5-1B). Subsequently, 
allogeneic islets modified with SA-FasL were transplanted on microporous scaffolds. Unmodified 
islets transplanted on scaffolds with transient rapamycin had rejection of the grafts, as indicated 
by increased blood glucose levels, by day 40 (Fig. 5-1B). Mice transplanted with allogeneic islets 
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modified with SA-FasL and receiving the transient rapamycin had normalized blood glucose levels 
that were sustained for 200 days (Fig. 5-1B), similar to the results with syngeneic islets. 
Rapamycin has been previously reported to synergize with FasL presentation to prolong graft 
survival [180], as either factor alone results in only short-term graft function. An IPGTT study 
demonstrated that the normalization of blood glucose levels by the transplanted islets was 
similar to that observed with naïve mice (i.e., non-diabetic) (Fig. 5-1C), which is consistent with 
previous reports of islets transplanted on scaffolds [122, 123].  
T cell proliferative responses were analyzed from the spleens and draining lymph nodes 
of the grafts. The collected cells were labeled with CFSE and used against BALB/c donor and third 
party C3H stimulators in a standard ex vivo mixed lymphocyte reaction. After 4 days of culture, 
the responses from CD8 T cells indicated similar proliferative responses for the SA-FasL islets, the 
unmodified islets, and an age-matched C57Bl6 control, with responses similar to both the donor 
and third party stimulators (Fig. 5-1D). Interestingly, CD4 T cell responses were greater for the 
SA-FasL modified islets relative to either the unmodified islets or age-matched control. This 
response was similar for both the donor and third party stimulators. These results demonstrate 
that CD4 and CD8 responsiveness is maintained outside the graft. Collectively, these studies 
demonstrate that the microporous scaffolds for transplantation of FasL modified islets to an 
extrahepatic, extra-renal site provides for engraftment of the islets and protection from the 
immune response similar to previous reports performed with transplantation into the kidney 
capsule or liver ([180, 184]). 
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5.3.2 Synthesis and characterization of biotin-poly(lactide-co-glycolide) conjugates and particle 
formation  
 While multiple strategies for functionalizing PLGA particles with ligands are available, 
evidence suggests that directly conjugating the polymer prior to particle fabrication enhances 




Figure 5-1. SA-FasL engineered islets establish allogeneic tolerance when transplanted on PLGA 
scaffolds. (A) Schematic showing biotinylated allogeneic islets functionalized with SA-FasL are 
loaded on microporous PLGA scaffolds and planted in the epididymal fat pad of mice. (B) Kaplan 
Meier analysis of allogeneic BALB/c islets transplanted under the short cover of rapamycin on 
unmodified PLGA scaffolds in C57BL/6 recipients. Conditions include SA-FasL-engineered islets (n 
= 5, MST >200 days, P=0.0018 vs. rapamycin alone, P=0.0308), naïve islets (n = 5, MST = 23 ±2.19 
days), and unmodified syngeneic islets (n = 3, MST > 100 days). (C) Intraperitoneal glucose 
tolerance test of long-term islet grafts compared to naïve C57BL/6 mice after fasting for 6 hours, 
followed by i.p. glucose injection. Blood glucose of mice was taken starting just before injection 
and at the indicated time points. (D) T cell proliferative response from recipients of long-term (> 
200 days) BALB/c SA-FasL-engineered islets mounted on unmodified PLGA scaffolds plus 
rapamycin (n = 3) and naïve C57BL/6 as controls (n = 3). Responders were labeled with CFSE and 
used against BALB/c donor and third party C3H stimulators in a standard ex vivo mixed 
lymphocyte reaction. After 4 days of culture, cells were stained with antibodies against CD4 and 
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CD8 molecules and incubated with 7AAD to gate out dead cells before flow cytometry analysis. 
Bars represent mean and SEM. Asterisks represent level of significance (*p<0.05, **p<0.01) 





was conjugated to the heterobifunctional linker NH2-PEG2-Biotin using carbodiimide chemistry 
and confirmed using 1H-NMR (Fig. 5-2A and 5-2B). Biotin-PLGA particles were prepared by 
employing a single emulsion-solvent evaporation procedure using the biotin-PLGA conjugates. 
The formed particles displayed an average size of 860 ± 40 nm and a zeta potential of –16 ± 5.0 
mV (Fig. 5-2C). SEM images confirmed the size and demonstrated the spherical morphology of 
the biotin-PLGA particles (Fig. 5-2D). When only biotin-PLGA was used in microparticle 
fabrication, particles did not form stable spheres (Fig. 5-3A). Thus, a 3:1 mix of biotin-PLGA to 
unmodified PLGA was used. When additional unmodified PLGA was blended in for a ratio of 1:1, 
there was no significant difference in the amount of protein absorbed at the concentrations 
tested (Fig. 5-3B). 
To demonstrate the ability of biotin-PLGA particles to load streptavidin-functionalized 
protein on their surface, we first quantified the maximum loading and efficiency of biotin-PLGA 
particle to load fluorescently-tagged streptavidin (AF568-SA) (Fig. 5-4A).  AF568-SA was 
incubated with biotin-PLGA particles at concentrations between 100 – 40,000 ng SA per mg of 
particles for 15 minutes. After incubation, the particles were with PBS to remove non-binding 
protein, dissolved in DMSO, and the fluorescence was measured (Fig. 5-4B). As expected, the 
loading of AF568-SA on the particles increased with increasing amounts of AF568-SA added but 
the loading did not increase linearly. The corresponding loading concentrations were 75 – 280 ng 
SA per mg of particles, and the loading efficiency (defined as the amount of protein bound divided 
by the amount incubated) decreased from 75% to 35% over this range as the particles became 
saturated with protein (Fig. 5-4C). A significant increase in the loading was observed between 





Figure 5-2. Characterization of biotin-PLGA microparticles. (A) Conjugation of NH2-PEG2-biotin to 
PLGA resulting in biotin-PLGA. (B) 1H-NMR of PLGA (top), biotin linker (middle), and biotin-PLGA 
(bottom). (C) Size (860 ± 40 nm) and charge (-15.8 ± 4.98 eV) of biotin-PLGA particles was 
measured using dynamic light scattering (DLS). (D) Scanning electron microscope (SEM) image of 











Figure 5-3. Blending unmodified PLGA with biotin-PLGA is necessary to consistently form 
spherical particles. (A) SEM image of particles formed only with biotin-PLGA formed unstable 
particles. (B) Two ratios of biotin-PLGA : PLGA (50:50 and 75:25) were analyzed. There was no 





400 ng/mg. This result was further supported by the measured loading efficiencies, where, as the 
amount of AF568-SA was increased, the loading efficiency decreased. Saturation of the particles 
was achieved by incubating the particles in a 40,000 ng SA per mg particles solution, which bound 
8600 ng SA per mg particles. To demonstrate that the protein binding is due to biotin-SA 
interaction and not passive adsorption of protein to the particle surface, unmodified PLGA 
particles were used as a control and demonstrated significantly lower binding and lower binding 
efficiency.  
Utilizing the information from the binding curves, it was determined that one milligram 
of particles incubated with 400 ng SA-FasL was optimal and this concentration was used for 
subsequent apoptosis assays. Particles were loaded with SA-FasL, washed three times with PBS, 
and incubated with 1.5 x 105 A20 cells (mouse B lymphoma cells) for 18 hours. Following 
incubation, cell death was quantified via propidium iodide (PI) live/dead stain and flow cytometry 
(Fig. 5-4D). As a positive control, soluble SA-FasL at concentrations known to induce apoptosis 
were included. While biotin-PLGA particles without FasL did not induce cell death, cells incubated 
with FasL-PLGA particles induced cell death in 50% of the population. 
5.3.3 FasL loading on biotin-PLGA scaffolds 
 Biotin-functionalized PLGA scaffolds were prepared by pressing biotin-PLGA and salt to 
form discs then gas foamed to fuse the particles (Fig. 5-5A). Following salt leach, porous scaffolds 
were left. In a similar manner to biotin-PLGA particles, the binding of SA-AF568 was evaluated by 
incubating the scaffolds with 100 to 800 ng SA-AF568 per mg of scaffold (one scaffold weighs 2.5 







Figure 5-4. Biotin-PLGA particles can be efficiently conjugated with SA-FasL and induce apoptosis 
in mouse B lymphoma cell line. (A) Schematic of biotin-PLGA particles being functionalized with 
SA-FasL. (B) The amount of fluorescently tagged SA bound to the particles was investigated by 
varying the protein concentration (0, 100, 200, 400, 800, and 40,000 ng SA/mL in 1 mL) incubated 
with 1 mg of biotin-PLGA particles (“biotin particles”). As a control, 1 mg of unmodified PLGA 
particles was incubated with the same SA concentrations (“blank particles”). After two spins and 
washes, particles were dissolved in DMSO and fluorescence was measured, n=3. (C) The loading 
efficiency was calculated by dividing the bound SA by the incubated SA, n=3. (D) Biotin-PLGA 
particles functionalized with SA-FasL induce cell death in A20 cells. Particles were incubated with 
400 ng / mL of SA-FasL in 1 mL with 1 mg of particles. After washing to remove unbound SA-FasL, 
particles were incubated with 1.5 x 105 A20 cells for 18 hours and cell death was analyzed via 
propidium iodide stain and flow cytometry (n=3). For comparison, soluble FasL was added to cells 





to 620 ng SA per mg of scaffold, which was similar to particles at low concentrations, but more 
than twice as much at higher concentrations. This difference may be due to increased surface 
area of the porous scaffold compared to the spherical particles. Additionally, the loading 
efficiency for all conditions tested was near 70% with no decline in efficiency at higher protein 
concentrations, indicating that the scaffolds are capable of binding protein at considerably higher 
concentrations than what was tested (Fig. 5-5C). Unmodified scaffolds were used as a control, 
and showed similar concentrations of non-specific binding to unmodified particles at higher 
protein concentrations.  
 The effectiveness of FasL-loaded scaffolds to induce apoptosis in immune cells was 
subsequently investigated by incubating the biotinylated scaffolds with SA-FasL, washing three 
times to remove unbound SA-FasL, and incubated with 1.5 x 105 A20 cells for 18 hours. Apoptosis 
induction was evaluated using PI/annexin V staining and quantified using flow cytometry (Fig. 5-
6A). The induction of apoptosis was concentration-dependent as 40 ng FasL/mg scaffold was not 
significantly different than the control but 200 ng/mg and 400 ng/mg increased apoptosis (Fig. 5-
6B).  These results demonstrate that FasL could be functionalized to the surface of PLGA scaffolds 
and induce apoptosis in immune cells. 
5.3.4 FasL scaffolds support allogeneic graft function without sustained immunosuppression 
We examined whether FasL modified scaffolds could prevent allogeneic islet rejection 
and support long-term engraftment and function of allogeneic islets to maintain normoglycemia. 
Scaffolds decorated with SA-FasL were loaded with 500-550 islets from BALB/c donors and 































Figure 5-5. Biotin-PLGA scaffolds can be efficiently conjugated with SA-FasL. (A) Schematic of 
biotin-PLGA particles functionalization with SA-FasL. (B) The amount of fluorescently tagged SA 
bound to scaffolds was investigated by varying the protein concentration (0, 100, 200, 400, and 
800 ng SA/20µL) incubated with 2.5 mg biotin-PLGA scaffolds (“biotin”). As a control, unmodified 
PLGA scaffolds were incubated with the same SA concentrations (“blank”). After two washes, 
scaffolds were dissolved in DMSO and fluorescence was measured, n=3. (C) The loading efficiency 















































Figure 5-6. FasL-decorated scaffolds induce apoptosis in mouse lymphoma cell line. (A) Scaffolds 
were incubated with SA-FasL (0, 40, 200, and 400 ng / 20 µL). After washing to remove unbound 
SA-FasL, scaffolds were incubated with 1.5 x 105 A20 cells for 18 hours. Apoptotic and dead cells 
were analyzed via propidium iodide and annexin V staining and flow cytometry (n=3). (B) 
Scaffolds required a minimum loading of 200 ng FasL / mg scaffold to induce apoptosis in the 
majority of A20 cells.  
0 ng FasL / mg scaffold 40 ng FasL / mg scaffold 200 ng FasL / mg scaffold 






mounted on SA-FasL-engineered PLGA scaffolds along with transient rapamycin demonstrated 
graft survival for more than 200 days in more than 80% of the animals (Fig. 5-7A), with one animal 
rejecting at day 30. Normoglycemia was established within days of transplantation (Fig. 5-7B), 
and an IPGTT performed at day 200 demonstrated restoration of normoglycemia on similar times 
as naïve animals (Fig. 5-7C). Rapamycin without FasL had a mean graft survival time of 23±2 days 
(Fig. 5-7A, B). The combination of SA-FasL-engineered islets mounted on SA-FasL-engineered 
PLGA scaffolds did extend graft function beyond that provided by rapamycin alone (Fig. 5-6A), 
yet unexpectedly was substantially shorter in duration (mean survival time = 46 days) than the 
SA-FasL engineered scaffolds. Prior to rejection, an IPGTT performed at day 200 demonstrated a 
restoration of euglycemia on the same time scales as naïve mice (Fig. 5-7C).  
5.4 Discussion 
This chapter investigated the combination of FasL and biomaterial scaffolds as a means 
to create a site that supports the engraftment and long term function of allogeneic islets at an 
extrahepatic and extrarenal site. Immunoprivileged sites, such as the testes, anterior chamber of 
the eye, brain, and tumors, have the ability to suppress destructive immune responses by various 
mechanisms [186-188]. Importantly, FasL was initially discovered as one of the molecules that 
plays a critical role in immunoprivileged sites [172, 173]. Indeed, we have recently reported that 
SA-FasL-engineered allogeneic islets induced localized immune privilege when transplanted 
under the kidney capsule [180]. Therefore, FasL not only contributes to the regulatory 
mechanisms in naturally occurring immunoprivileged sites in the body, but can also be used to 







Figure 5-7: Islets on scaffolds conjugated with SA-FasL demonstrate robust long-term tolerance. 
(A) Survival of allogeneic BALB/c islets mounted on PLGA scaffolds and transplanted in the 
epididymal fat pad of chemically diabetic C57BL/6 recipients. Groups included naïve islets 
mounted on SA-FasL-engineered PLGA scaffolds plus rapamycin (n = 6, MST > 200 days, P=0.0007 
vs rapamycin alone), SA-FasL-engineered islets mounted on SA-FasL-engineered PLGA scaffolds 
(n = 6, MST = 46 days, P = 0.0007 vs rapamycin alone), and naïve islets transplanted under a short 
cover of rapamycin (n = 5, MST = 23 ±2.19 days). All mice received islets loaded on 2 PLGA 
scaffolds. PLGA scaffolds were engineered with 2.5 μg/scaffold, except 3 mice in the islet-
FasL+PLGA-SA-FasLthat were transplanted with PLGA scaffolds engineered with 0.5μg/scaffold 
and all 3 animals rejected their grafts. Rapamycin was given to the indicated groups through i.p. 
injection at 0.2 mg/kg daily for 15 days starting on the day of transplantation. Mice were 
monitored twice weekly for blood glucose levels. Those with > 250 mg/dL for two consecutive 
readings 24 hours apart were considered diabetic and rejecting the graft. Analysis done using log-
rank test, **P<0.01, ***P<0.001. (B) Blood glucose readings of two groups of mice from (A). (C) 
Intraperitoneal glucose tolerance test (IPGTT) of long-term islet grafts compared to naïve 
C57BL/6 mice after fasting for 6 hours, followed by i.p. glucose injection. Blood glucose of mice 





was 100% effective, the SA-FasL immunomodulatory protocol had moderate efficacy in inducing 
tolerance to allogeneic islets transplanted intraportally as practiced in the clinic [184]. This 
finding provided rationale for the development of an extrahepatic site for islet transplantation. 
Herein, we demonstrated that allogeneic SA-FasL-engineered islets engrafted and normalized 
blood glucose levels for more than 200 days under a transient cover of rapamycin (0.2 mg/kg 
daily starting the day of transplantation for a total of 15 doses) with transplantation on PLGA 
scaffold into an extrahepatic site, one that has translational potential [38]. 
Given that localized presentation of SA-FasL on islets supported long-term function, we 
subsequently investigated the immobilization of SA-FasL to the scaffold as a means to minimize 
the cellular manipulation prior to transplantation. Manipulating the scaffold to present SA-FasL 
would eliminate the steps needed for direct islet engineering, and as such save time and 
overcome potential undesired effects associated with engineering process, such as cell 
fragmentation. Importantly, the presentation of SA-FasL from surfaces has previously been 
reported not to interfere with its apoptotic function [180, 189]. To create scaffolds modified with 
SA-FasL, we initially modified the polymer in solution [190, 191], which was subsequently formed 
in to particles and then into scaffolds. Initial attempts to functionalize scaffolds involved 
conjugation of biotin to the surface of a pre-formed scaffold, which produced inconsistent 
modification with SA-FasL and thus the direct modification of the polymer was pursued based on 
prior reports indicating enhanced target binding [185]. Stable spherical particles could only be 
formed from mixtures of the biotinylated and non-biotinylated polymer, as particles formed from 
only biotinylated polymer were unstable. The microspheres were employed to construct the 
scaffold using a gas foaming and particulate leaching process [39, 118, 192]. As a potential off-
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the-shelf product, further studies will be needed to test long-term storage of SA-FasL pre-
engineered scaffolds for downstream applications. 
The microporous structure of the scaffold enhanced protein loading and bioactivity 
relative to the particles. This observation likely results from the higher surface area of the 
scaffolds. Protein loading and efficiency were similar to other techniques like carbodiimide 
coupling to PLGA particles [193, 194]. The presentation of SA-FasL from particles or scaffolds 
maintained the ability to induce apoptosis, although it was not as efficient as delivering soluble 
SA-FasL which induced apoptosis with 10 ng, which may reflect the availability of FasL for binding 
to receptors. Interestingly, for concentrations between 40 and 400 ng/mg, the extent of binding 
was highly consistent within experiments (i.e., low standard deviation), yet considerable 
variation in apoptosis was observed between experiments, suggesting a sensitivity to the protein 
loading or presentation within this range. Previous reports of surface modified apoptosis systems 
utilized surface anchored polymer chains with covalently linked anti-Fas antibodies but were only 
able to achieve up to 34% apoptosis in cells expressing FasR, whereas the method presented here 
achieved 92% apoptosis and in vivo protection of allogeneic islets [195]. This may be due to the 
far greater surface density of protein (up to 150 ng/cm2 vs 1.6 ng/cm2) and the choice FasR 
binding protein. 
Importantly, microporous scaffolds functionalized with SA-FasL supported engraftment 
and function of the transplanted allogeneic islets that maintained normoglycemia for more than 
200 days. Islets transplanted on unmodified PLGA scaffolds promptly rejected 6-12 days after the 
rapamycin treatment ended, consistent with our previous results [180]. This long-term function 
without immunosuppression has a likely contribution from rapamycin allowing for the expansion 
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of regulatory T cells, an important cell population in establishing alloimmunity [180]. SA-FasL 
alone without rapamycin was able to delay rejection, consistent with previous reports suggesting 
that tolerance is dependent on the presence of SA-FasL yet a short course of rapamycin may 
accentuate the effect. In conclusion, our approach of functionalizing SA-FasL onto the surface of 








CHAPTER 6. Conclusions and Future Directions 
 
6.1 Conclusions 
Type 1 Diabetes can be successfully treated with islet transplants to restore the body’s 
ability to endogenously produce insulin and rapidly respond to changes in blood glucose levels. 
However, current clinical practice requires an unsustainable number of donors and long-term 
success is limited. This may change if we are able to engineer an alternative transplant site that 
does not suffer from immediate islet loss and provides long-term protection from the immune 
system.  
Herein, we present the utility of encapsulating and microporous PEG hydrogels for islet 
transplantation and subsequent engraftment in vivo in a syngeneic mouse model of diabetes. 
Hydrogels are employed as a substrate that creates a space to promote regeneration, possess 
mechanical properties similar to native extracellular matrices, and can be readily functionalized.  
In an allogeneic model, encapsulating hydrogels and microporous hydrogels containing islets 
rejected in a similar timeframe, demonstrating that unmodified PEG hydrogels do not offer 
sufficient allogeneic protection. This result underscores the need for sustained release strategies 
and incorporation of cytokine antagonists to further protect islets, in either encapsulating or 
microporous materials, from apoptosis. These findings provide a basis for continued studies with 
allogeneic islets and demonstrate the need for improvements in delivery of immune-modulating 
agents to extend graft function. 
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Viral gene delivery represents a versatile tool to modify the microenvironment of 
damaged or diseased tissue and promote regeneration by converting the transduced cells into 
bioreactors to produce therapeutic proteins or downregulate undesired genes. Hydrogels 
functionalized with proteins or peptides capable of binding lentivirus retained the virus at the 
material, enhanced the virus stability, and ultimately promoted gene transfer. High molecular 
weight proteins that non-specifically bind the lentivirus were directly attached to support binding 
and gene transfer. Alternatively, short peptides that specifically bind the lentivirus had to be 
immobilized onto biomaterials through linkers in order to promote binding and gene transfer, 
yet offered comparable gene expression levels. Taken together, affinity peptides or proteins can 
be attached to biomaterials to promote the binding of gene therapy vectors and subsequent gene 
transfer, with the efficiency a function of the peptide length and binding affinity. 
The surface of biomaterial scaffolds were modified with SA-FasL to create a localized 
immunoprivileged site and provide long-term protection and function. Initial studies utilized 
allogeneic islets modified with SA-FasL seeded on PLGA microporous scaffolds to establish long-
term tolerance. As an alternative to modifying islets, PLGA was conjugated with biotin that 
created a fast and efficient method to present SA-FasL on the polymer surface at concentrations 
that induced apoptosis in cells expressing FasR. Scaffolds functionalized with FasL demonstrated 
robust engraftment and tolerance similar to the FasL functionalized islets. In summary, this study 
introduces a new method to surface functionalize PLGA particles and scaffolds with 
immunoregulatory proteins and offers an alternative to systemic immunosuppression for 
allogeneic islet transplants.  
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6.2 Future directions 
6.2.1 Scaffold improvement 
 Future work should focus on the PEG microporous scaffolds as they provided better 
glucose response and faster tissue infiltration compared to the encapsulating hydrogels. 
Without significant modification to address inflammatory cytokine infiltration, the 
encapsulating hydrogels do not offer significant protection in the allogeneic transplant model. 
Additionally, scale up of the current macroencapsulating design poses serious challenges. In 
contrast, the microporous hydrogels are easily scalable and have already been modified for 
non-human primate studies in a collaboration with the Oberholzer lab at the University of 
Illinois at Chicago. Future improvements to the hydrogel can optimize the pore size. Based on 
simulations, the ideal pore size in PEG hydrogels is 160 to 270 µm, whereas the pore sizes 
presented here were just above and below the suggested range. Micropore size is readily 
adjusted by adding different grain size salt, which is sorted by a series of simple mechanical 
sieves. To improve ease of transplant, we recommend future hydrogels utilize a smaller mold 
than the current 5 mm diameter PDMS mold. After swelling, the hydrogels are approximately 
6.5 mm in diameter, making implantation into a diabetic mouse’s epididymal fat pad 
challenging. Based on preliminary experiments, a 3 mm mold produced hydrogels too small to 
properly load desired volumes of islets. Thus, a 4 mm diameter mold is predicted to balance 
scaffold size and loading capacity.  
Although encapsulating hydrogels inherently limit vascularization, a hybrid design that 
incorporates microporous aspects into an encapsulated hydrogel may improve glucose 
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response. Efforts to increase surface area of macroencapsulated islets has seen early success in 
PEG hydrogels and has been translated into the clinic in devices like the TheraCyte System and 
Nanogland device [41, 196, 197]. If scaffold degradation for the microporous or encapsulating 
hydrogel is required, plasmin-degradable peptides (e.g. YKNR) can be incorporated into the 
design, thus allowing the hydrogel to degrade as cells infiltrate and establish native ECM. 
Although not the focus of this dissertation, stem cells have the capacity for infinite expansion 
and are a renewable source, but require a microenivornment that promotes stem cell 
maturation. Degradable microporous hydrogels might be useful for β-progenitor stem cells as 
they provide a three-dimensional environment for cell-material signaling during stem cell 
maturation.  
6.2.2 Localized protein delivery from biomaterial scaffolds 
In the context of islet transplantation, a sophisticated release system may be needed to 
promote long-term engraftment. Such a delivery system would deliver a combination of agents 
in phases, designed to coincide with host immune response to transplanted islets. The short-term 
release of anti-inflammatory molecules like TGF-β1 coupled with long-term tolerance provided 
by FasL may provide synergy and enhance graft function beyond their individual components. To 
further modify the microenvironment, lentiviral vectors can transduce infiltrating cells to 
produce a variety of growth factors and inhibitors. 
The release profile of soluble factors from PLGA discs implanted with PEG scaffolds can 
be modified by adjusting the ratio of lactic acid to glycolic acid monomers or modifying the 
carboxylic acid end group to control the rate of polymer hydrolysis [198]. However, based on the 
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rate of protein release from the disc, the release kinetics are likely primarily determined by the 
dissolution of the mannitol cryoprotectant. Replacing the mannitol with a slower dissolving sugar 
may not only extend the release profile, but reduce protein lost during the salt leaching step. In 
an effort to address this protein loss during the leaching step, we have developed a PDMS insert 
that is placed in the mold with the PEG and salt instead of the PLGA disc. After polymerization 
and porogen leaching, the insert is pulled out and the protein loaded disc is slid in. However, this 
process has not been tested and it is unknown if the PLGA disc can slip out when transplanted in 
an animal. 
Localized lentiviral delivery from hydrogels is a versatile tool that allows for the delivery 
and long-term expression of a wide range of therapeutic proteins and small molecules in 
scaffold microenvironment. VEGF is a particularly attraction option, as it has been extensively 
utilized in bioengineering to stimulate angiogenesis, a critical requirement for the survival of 
insulin producing cells [199, 200]. Additionally, sustained expression of exendin-4 (Ex4), an 
insulin-like growth factor-1 (IGF-1) has demonstrated useful applications in enhancing islet 
function [123, 201]. Long-term tolerance from these hydrogel scaffolds may be achieved by 
functionalizing SA-FasL to their surface. PEG-maleimide is easily functionalized with a biotin-
PEG-thiol linker in a single step reaction that that requires no purification. Taken together, the 
tools presented in this dissertation can be applied to treat T1D and may someday be used to 
develop minimally invasive techniques that do not require chronic immune suppression to 
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